



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 405/04, 409/04, 403/04, 401/04, 241/44, 417/04, 413/04, A61K 31/495	A1	(11) International Publication Number: WO 99/42463 (43) International Publication Date: 26 August 1999 (26.08.99)
(21) International Application Number: PCT/US99/02581 (22) International Filing Date: 5 February 1999 (05.02.99) (30) Priority Data: 60/075,551 23 February 1998 (23.02.98) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CARSON, Kenneth, G. [US/US]; 22 Alfrenton Road, Needham, MA 02494 (US). CONNOR, David, Thomas [GB/US]; 2453 Antietam, Ann Arbor, MI 48105 (US). LI, Jie, Jack [US/US]; 258 Village Green Boulevard #101, Ann Arbor, MI 48105 (US). LOW, Joseph, Edwin [-/US]; 921 Alpine Court, Brighton, MI 48116 (US). LULY, Jay, R. [US/US]; 24 Damien Road, Wellesley, MA 02494 (US). MILLER, Steven, Robert [US/US]; 4450 Hillside Court, Ann Arbor, MI 48105 (US). ROTH, Bruce, David [US/US]; 49255 Hunt Club Court, Plymouth, MI 48170 (US). TRIVEDI, Bharat, Kalidas [IN/US]; 36955 Aldergate Court, Farmington Hills, MI 48335 (US).		(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al. (81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS (57) Abstract <p>Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic dermatitis, disease associated with pathological angiogenesis (i.e. cancer), asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS

BACKGROUND OF THE INVENTION

The present invention relates to novel quinoxaline compounds useful as
5 pharmaceutical agents, to methods for their production, to pharmaceutical
compositions which include these compounds and a pharmaceutical carrier, and to
pharmaceutical methods of treatment. The compounds of the present invention are
Interleukin-8 (IL-8) receptor antagonists. More particularly, the compounds of the
present invention are useful in the treatment of a chemokine-mediated disease
10 wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such
as, for example, a chemokine-mediated disease selected from psoriasis, or atopic
dermatitis, tumor growth and angiogenesis, asthma, chronic obstructive
pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory
bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock,
15 endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and
renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease,
graft versus host reaction, allograft rejections, or allergic diseases.

IL-8 is a 72 amino acid protein which is a member of the superfamily of
leukocyte chemoattractant proteins which have been referred to as intercrines,
20 C-X-C or C-C cytokines or, more recently as chemokines (Oppenheim J.J. et al.,
"Properties of the novel proinflammatory supergene "intercrine" cytokine family."
Annu. Rev. Immunol., 1991;9:617-648). Many members of the chemokine family
appear to be involved in the inflammatory process and in the trafficking of
leukocytes. The chemokine superfamily is composed of two branches: the α - and
25 the β -chemokines. The α -chemokine branch includes IL-8, neutrophil activating
peptide-2 (NAP-2), melanoma growth stimulatory activity (MGSA/gro or GRO α),
and ENA-78, all of which have attracting and activating effects predominantly on
neutrophils. This branch also includes PF4, β -thromboglobulin, and CTAPIII,
which do not affect neutrophils.

-2-

IL-8 was originally identified by its ability to both attract and activate polymorphonuclear leukocytes (neutrophils) and has now been shown to be rapidly induced in a wide variety of cell and tissue types in response to pro-inflammatory cytokines such as IL-1b or TNF α . Additionally, there is data demonstrating high systemic levels of IL-8 in certain neutrophil-mediated inflammatory diseases, suggesting the IL-8 and closely related factors may be the principal endogenous mediators of neutrophil activation. Many reports have been published regarding disorders in which high levels of IL-8 have been measured, and include rheumatoid arthritis, septic shock, asthma, cystic fibrosis, myocardial infarction, and psoriasis (Baggiolini et al., *FEBS Lett.*, 1992;307:97; Miller et al., *Crit. Rev. Immunol.*, 1992;12:17. Oppenheim et al., *Annu. Rev. Immunol.*, 1991;9:617; Seitz et al., *J. Clin. Invest.*, 1991;87:463; Miller et al., *Am. Rev. Respir. Dis.*, 1992;146:427; Donnely et al., *Lancet*, 1993;341:643). Strong in vivo evidence indicating a central role of IL-8 in the pathology related to lung ischemia/reperfusion has recently been published (Sekido N., Mukaida N. et al., "Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8." *Nature*, 1993;365(6447):654-7 Issn: 0028-0836). A monoclonal antibody to rabbit IL-8, capable of blocking the in vitro neutrophil chemotactic activity of IL-8, prevented tissue damage in the rabbit lung normally resulting from lung ischemia/reperfusion. More recently, another study has shown beneficial effects of an IL-8 neutralizing antibody in an endotoxin-induced pleurisy model in rabbit (Broaddus V.C., Boylan A.M. et al., "Neutralization of IL-8 inhibits neutrophil influx in a rabbit model of endotoxin-induced pleurisy," *J. Immunol.*, 1994;152(6):2960-2967). There were also reports indicating similar beneficial effects with IL-8 neutralizing antibodies in animal models of dermatitis, joint arthritis, and glomerulonephritis. Additionally, knockout mice have been generated in which the apparent mouse homologue of the IL-8R (closer to IL-8RB) was deleted by homologous recombination (Cacalano G., Lee J. et al., "Neutrophil and b cell expansion in mice that lack the murine IL-8 receptor homolog," *Science*, 1994;265(5172):682-4 Issn: 0036-8075). Although these mice appear healthy, their neutrophils are greatly impaired, as compared to wild-type mice, in their ability to migrate to the peritoneum in response to intraperitoneal


-3-

thioglycollate injection. All of these results suggest that IL-8 is an important mediator of neutrophil migration and activity in some inflammatory settings, and that a small molecule antagonist to the receptors for IL-8 should prove to be an effective treatment for some inflammatory pathologies and has the potential to be a broadly useful anti-inflammatory agent. Also, there have been reports that IL-8 is an important cytokine involved in tumor growth and angiogenesis in a variety of malignancies (Hebert et al., *Cancer Invest.*, 1993;11:743 and Richards et al., *American Journal of Surgery*, 1997;174:507).


We have identified a series of quinoxalines that are IL-8 receptor antagonists and which can additionally be used in psoriasis, or atopic dermatitis, disease associated with pathological angiogenesis (i.e. cancer), asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.

SUMMARY OF THE INVENTION

Accordingly, a first aspect of the present invention is a compound of Formula I



wherein A is selected from the group consisting of:



wherein R³, R^{3a}, and R^{3b} are each independently the same or

different and are hydrogen,

alkyl,

-4-

aryl-SO₂-,

aryl,

heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

5

alkyl,

aryl,

aralkyl,

acetyl, or

10

-(CH₂)_m-N-R⁵ wherein
$$\begin{array}{c} | \\ R^6 \end{array}$$

R⁵ and R⁶ are each the same or different and are hydrogen,
alkyl, cycloalkyl, acetyl, -(CH₂)_m-OH, or

15

R⁵ and R⁶ are taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or N-R⁴ wherein R⁴ is as defined above and
m is an integer of 2 to 5,

-(CH₂)_n-N-R⁷ wherein n is zero or an integer of 1 and R⁷ and R⁸ are

20

$$\begin{array}{c} | \\ R^8 \end{array}$$

each independently the same or different and are hydrogen,

alkyl,

aryl,

aralkyl,

25












acetyl, or

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are as defined
$$\begin{array}{c} | \\ R^6 \end{array}$$





30

above or R⁷ and R⁸ taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or N-R⁴ wherein R⁴ and m are as defined
above,





-5-






-6-








5







-7-

and R^{3a} are as defined above,





5











-8-



5






-9-






wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 and R^{3a} are as defined above,

5


-10-




5




10




-11-

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined

above,

wherein R^3 , R^{3a} , and R^{3b} are as defined



above,




halogen, or

alkoxy, with the proviso

10

wherein R^3 is hydrogen, methyl, orwherein R^3 is hydrogen; and R^2 is CF_3 , CCl_3 , CBr_3 , or


15

wherein R^{10} is hydrogen,


alkyl, or

-12-


aralkyl,



defined above,



5




10




independently the same or different and are hydrogen, alkyl,
or aryl, or taken together can form a 5- to 7-membered ring,
and

15


R¹³ is hydrogen or alkyl, and
m is as defined above,







20



-13-



above,




R¹⁰ and R¹¹ when taken together can form a 5- to 7-membered ring optionally containing an oxygen atom or N-R⁴ wherein R⁴ is as defined above;

10 or a pharmaceutically acceptable salt thereof.

A second aspect of the present invention is a method of treating a chemokine-mediated disease state, wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor in a mammal, which comprises administering to said mammal an effective amount of compound of Formula II


15



II

wherein A is selected from the group consisting of:

-14-



wherein R^3 , R^{3a} , and R^{3b} are each independently the same or

different and are hydrogen,

alkyl,

aryl-SO₂-,

5

aryl,

heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

alkyl,

aryl,

10

aralkyl,

acetyl, or

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are each the same or different



15

and are hydrogen,

alkyl, cycloalkyl, acetyl, -(CH₂)_m-OH, or

R⁵ and R⁶ are taken together to form a 5- to

7-membered ring optionally containing an oxygen

atom or N-R⁴ wherein R⁴ is as defined above and

20

m is an integer of 2 to 5,

-(CH₂)_n-N-R⁷ wherein n is zero or an integer of 1 and R⁷ and R⁸ are



each independently the same or different and are hydrogen,

25


alkyl,

aryl,






aralkyl,

acetyl, or

-15-



5 R^7 and R^8 taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or $\text{N}-\text{R}^4$ wherein R^4 and m are as defined above,






halogen,

CF_3 ,





CBr_3 ,




NO_2 ,






-16-







5




alkyl;






-17-







5







and R^{3a} are as defined above,




-18-









5



-19-





wherein R³, R^{3a}, and R^{3b} are as defined

above,





wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,

5










-20-



5



-21-



-22-

alkyl,

halogen,

alkoxy,

-OR⁴ wherein R⁴ is as defined above, or

5 $-(\text{CH}_2)_n\text{-N-R}^7$ wherein R^7 , R^8 , and n are as defined above; and
 $\quad \quad \quad |$
 $\quad \quad \quad \text{R}^8$

R^{2a} is CF₃,

 CCl_3 ,

10 CBr₃, or

$$\begin{array}{c} -N-R^{10} \\ | \\ R^{11} \end{array}$$

wherein R¹⁰ is hydrogen,

15 alkyl, or

aralkyl, and

$$R^{11} \text{ is } \text{---} \langle \text{benzene ring} \rangle \text{---} (\text{CH}_2)_n \text{---} \text{N} \begin{matrix} \text{---} R^5 \\ | \\ R^6 \end{matrix}$$

wherein n , R^5 , and R^6 are as defined above,

20 $-(CH_2)_m-N-R^5$ wherein R^5 , R^6 , and m are as defined
 $\quad \quad \quad |$
 $\quad \quad \quad R^6$

above,

25
$$-(\text{CH}_2)_m-\text{N}(\text{R}^{12})-\text{C}(\text{N-R}^{13})(\text{R}^{12a})-\text{N-R}^{12}$$
 wherein R¹² and R^{12a} are each

independently the same or different and are

hydrogen,

30 alkyl, or


-23-

aryl, or taken together can form a 5- to
7-membered ring, and

R¹³ is hydrogen or alkyl, and




m is as defined above,

5




10

defined above,




15

above,




defined above,





above,

20



-24-



R¹⁰ and R¹¹ when taken together can form a 5- to 7-membered ring
optionally containing an oxygen atom or N-R⁴ wherein R⁴ is as
defined above;

or a pharmaceutically acceptable salt thereof.

As inhibitors of chemokine-mediated diseases, the compounds of
Formula I and II can be used as agent for treating psoriasis, or atopic dermatitis,
disease associated with pathological angiogenesis (i.e. cancer), asthma, chronic
obstructive pulmonary disease, adult respiratory distress syndrome, arthritis,
inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer,
septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome,
stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis,
Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic
diseases.

A still further embodiment of the present invention is a pharmaceutical
composition for administering an effective amount of a compound of Formula I or
Formula II in unit dosage form in the treatment methods mentioned above.
Finally, the present invention is directed to methods for production of compounds
of Formula I or Formula II.

DETAILED DESCRIPTION OF THE INVENTION

In the compounds of Formula I or II, the term "alkyl" means a straight or
branched hydrocarbon radical having from 1 to 8 carbon atoms and includes, for
example, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, sec-butyl, isobutyl,
tert-butyl, *n*-pentyl, *n*-hexyl, *n*-heptyl, *n*-octyl, and the like.

-25-

The term "cycloalkyl" means a saturated hydrocarbon ring which contains from 3 to 8 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.

5 "Alkoxy" and "thioalkoxy" are O-alkyl or S-alkyl of from 1 to 6 carbon atoms as defined above for "alkyl".

The term "aryl" means an aromatic radical which is a phenyl group, a phenyl group substituted by 1 to 4 substituents selected from alkyl as defined above, alkoxy as defined above, thioalkoxy as defined above, hydroxy, halogen, trifluoromethyl, amino, alkylamino as defined above for alkyl, dialkylamino as

10 defined for alkyl, nitro, cyano, carboxy, SO_3H , CHO , $\overset{\text{O}}{\parallel}\text{-C-alkyl}$ as defined above

15 for alkyl, $\overset{\text{O}}{\parallel}\text{-C-NH}_2$, $\overset{\text{O}}{\parallel}\text{-C-NH-alkyl}$ as defined above for alkyl, $\overset{\text{O}}{\parallel}\text{-C-N(alkyl)}_2$ as defined above for alkyl, $\text{-(CH}_2\text{)}_n\text{-NH}_2$ wherein n is an integer of 1 to 5, $\text{-(CH}_2\text{)}_n\text{-NH-alkyl}$ as defined above for alkyl and n, $\text{-(CH}_2\text{)}_n\text{-N(alkyl)}_2$ as defined above for alkyl and n.

20 The term "heteroaryl" means a heteroaromatic radical which is 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2,3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridinyl, 3-, 4-, or 5-pyridazinyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, N-formyl-2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]furanyl, or 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl, unsubstituted or substituted by one to three substituents selected from alkyl as defined above, alkoxy as defined above, thioalkoxy as defined above, hydroxy, halogen, trifluoromethyl, amino, alkylamino as defined above for alkyl, dialkylamino as

30

defined for alkyl, nitro, cyano, carboxy, SO_3H , CHO , $\overset{\text{O}}{\parallel}\text{-C-alkyl}$ as defined above

-26-

for alkyl, $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-\text{NH}_2 \end{array}$, $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-\text{NH}-\text{alkyl} \end{array}$ as defined above for alkyl, $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-\text{N}(\text{alkyl})_2 \end{array}$ as defined above for alkyl, $-(\text{CH}_2)_n-\text{NH}_2$ wherein n is an integer of 1 to 5, $-(\text{CH}_2)_n-\text{NH}-\text{alkyl}$ as defined above for alkyl and n, $-(\text{CH}_2)_n-\text{N}(\text{alkyl})_2$ as defined above for alkyl and n.

The term "aralkyl" or "arylalkyl" means an aromatic radical attached to an alkyl radical wherein "aryl" and "alkyl" are as defined above, for example, benzyl, fluorenylmethyl, and the like.

The term "5- to 7-membered ring optionally containing an oxygen atom or N-R⁴" includes, for example, pyrrolidine, pyrrolizidine, imidazolidine, oxazolidine, piperidine, piperazine, morpholine, homopiperidine, and the like. The carbon atoms of the above 5- to 7-membered ring may be substituted independently by alkyl, amino, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, carboxy, carboxyalkyl, alkylcarboxyalkyl, thio, thioalkyl, alkylthioalkyl, hydroxy, hydroxyalkyl, alkoxy, or alkoxyalkyl.

In the compounds of Formula I or II, any unsubstituted carbon atoms of a bicyclic or tricyclic heteroaromatic moiety at R¹ or R^{1a} may be substituted by R³, R^{3a}, or R^{3b}.

"Halogen" is fluorine, chlorine, bromine, or iodine.

Some of the compounds of Formula I or II are capable of further forming both pharmaceutically acceptable acid addition and/or base salts. All of these forms are within the scope of the present invention.

Pharmaceutically acceptable acid addition salts of the compounds of Formula I or II include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide,

-27-

acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M. et al, "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977;66:1).

The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge S.M. et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977;66:1).

The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention.


Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated

-28-

forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. Additionally, the compounds of the present invention may exist as geometric isomers. The present invention includes all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof.

A preferred compound of Formula I in the first aspect of the present invention is one wherein A is selected from the group consisting of:



wherein R^3 , R^{3a} , and R^{3b} are each independently the same or

different and are hydrogen,

alkyl,

aryl,

heteroaryl,

$-OR^4$ wherein R^4 is hydrogen,

alkyl,

aryl,

aralkyl,

acetyl, or

$-(CH_2)_m-N-R^5$ wherein R^5 and R^6 are each the same or



different and are hydrogen,

alkyl, cycloalkyl, acetyl, or

R^5 and R^6 are taken together to form a 5- to

7-membered ring optionally containing an oxygen

-29-

atom or N-R⁴ wherein R⁴ is as defined above and
m is an integer of 2 to 5,

-(CH₂)_n-N-R⁷ wherein n is zero or an integer of 1 and R⁷ and R⁸ are



each independently the same or different and are hydrogen,

alkyl,

aryl,

aralkyl,

10 acetyl, or

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are as defined



15 above or R⁷ and R⁸ taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or N-R⁴ wherein R⁴ and m are as defined
above,

-(CH₂)_n-CON-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂N-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂OR⁴ wherein R⁴ and n are as defined above,

25 -(CH₂)_n-CO₂R⁴ wherein R⁴ and n are as defined above,

-CH₂OR⁴ wherein R⁴ is as defined above,

halogen,





CF₃,

CBr₃,





30 CCl₃, or

NO₂,





-30-

wherein R³ and R^{3a} are as defined above,wherein R³ and R^{3a} are as defined above,wherein R³ and R^{3a} are as defined above, orwherein R³ and R^{3a} are as defined above;





5

R¹ iswherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,









-31-



5



-32-

wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 and R^{3a} are as defined above,wherein R^3 and R^{3a} are as defined above,

halogen, or


-33-

alkoxy; and

R² is CF₃,CCl₃,CBr₃, or


5 -N-R¹⁰ wherein R¹⁰ is hydrogen and
 |
 R¹¹

10 R¹¹ is -(CH₂)_m-N-R⁵ wherein m, R⁵, and R⁶ are as defined above,
 |
 R⁶

or —(CH₂)_n——N—R⁵ wherein n, R⁵, and R⁶ are as
 |
 R⁶

defined above.

A more preferred compound of Formula I in the first aspect of the present invention is one wherein A is



different and are hydrogen,

alkyl,

aryl,

heteroaryl,

20 -OR⁴ wherein R⁴ is hydrogen,

alkyl,

aryl,

aralkyl,

acetyl, or


25 -(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are each the same
 |
 R⁶

-34-

or different and are hydrogen,

alkyl, cycloalkyl, acetyl, or

R^5 and R^6 are taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or $N-R^4$ wherein R^4 is as defined above and
 m is an integer of 2 to 5,




each independently the same or different and are hydrogen,

alkyl,






aryl,

aralkyl,

acetyl, or




above or R^7 and R^8 taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or $N-R^4$ wherein R^4 and m are as defined
above,








halogen,

 CF_3 ,


-35-

CBr₃,CCl₃, orNO₂;



5




10



-36-

wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,


or

wherein R^3 and R^{3a} are as defined above; and


- 5 R^2 is CF_3 ,
 CCl_3 ,
 CBr_3 , or
 $-N-R^{10}$ wherein R^{10} is hydrogen and
 $|$
 R^{11}

10

R^{11} is $-(CH_2)_m-N-R^5$ wherein m , R^5 , and R^6 are as defined above, or
 $|$
 R^6



- 15 Another more preferred compound of Formula I in the first aspect of the present invention is one wherein A is

wherein R^3 , R^{3a} , and R^{3b} are each independently the same or

different and are hydrogen,

alkyl,

-37-

aryl,

heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

alkyl,

5

aryl,

heteroaryl,

aralkyl,

acetyl, or

10

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are each the same or

different and are hydrogen,

alkyl, cycloalkyl, acetyl, or

15

R⁵ and R⁶ are taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or N-R⁴ wherein R⁴ is as defined above and
m is an integer of 2 to 5,

-(CH₂)_n-N-R⁷ wherein n is zero or an integer of 1 and R⁷ and R⁸ are

20



each independently the same or different and are hydrogen,

alkyl,

aryl,

aralkyl,

25

acetyl, or

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are as defined

30

above or R⁷ and R⁸ taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or N-R⁴ wherein R⁴ and m are as defined
above,

-38-

-(CH₂)_n-CON-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂N-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂OR⁴ wherein R⁴ and n are as defined above,

-(CH₂)_n-CO₂R⁴ wherein R⁴ and n are as defined above,

-CH₂OR⁴ wherein R⁴ is as defined above,

halogen,


CF₃,

CBr₃,


CCl₃, or

NO₂;


15

R¹ is


wherein R³, R^{3a}, and R^{3b} are as defined above,




wherein R³, R^{3a}, and R^{3b} are as defined above,



wherein R³, R^{3a}, and R^{3b} are as defined above,





wherein R³, R^{3a}, and R^{3b} are as defined above,




wherein R³, R^{3a}, and R^{3b} are as defined above,

-39-

wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined


above, or

wherein R^3 and R^{3a} are as defined above; and

5 R^2 is CF_3 ,
 CCl_3 ,
 CBr_3 , or


10 $-N-R^{10}$ wherein R^{10} is hydrogen and
 $|$
 R^{11}

R^{11} is $-(CH_2)_m-N-R^5$ wherein m , R^5 , and R^6 are as defined above, or
 $|$
 R^6



15 defined above.

A most preferred compound of Formula I in the first aspect of the present invention is one wherein A is

wherein R^3 , R^{3a} , and R^{3b} are each independently the same or

different and are hydrogen,

-40-

alkyl,

aryl,

heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

5

alkyl,

aryl,

aralkyl,

acetyl, or

10

-(CH₂)_m-N-R⁵ whereinR⁵ and R⁶ are each the same or different and are hydrogen,

alkyl, cycloalkyl, acetyl, or

15

R⁵ and R⁶ are taken together to form a 5- to

7-membered ring optionally containing an oxygen

atom or N-R⁴ wherein R⁴ is as defined above and

m is an integer of 2 to 5,

-(CH₂)_n-N-R⁷ wherein n is zero or an integer of 1 and R⁷ and R⁸ are

20



each independently the same or different and are hydrogen,

alkyl,

aryl,

aralkyl,

25

acetyl, or

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are as defined

30

above or R⁷ and R⁸ taken together to form a 5- to

7-membered ring optionally containing an oxygen

atom or N-R⁴ wherein R⁴ and m are as defined

above,

-41-

-(CH₂)_n-CON-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂N-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂OR⁴ wherein R⁴ and n are as defined above,

-(CH₂)_n-CO₂R⁴ wherein R⁴ and n are as defined above,

-CH₂OR⁴ wherein R⁴ is as defined above,

halogen,


CF₃,

CBr₃,


CCl₃, or

NO₂;


15

R¹ is


wherein R³, R^{3a}, and R^{3b} are as defined above,




wherein R³, R^{3a}, and R^{3b} are as defined above,



wherein R³, R^{3a}, and R^{3b} are as defined above,



wherein R³, and R^{3a} are as defined above,




wherein R³, R^{3a}, and R^{3b} are as defined above,

20

or


-42-

wherein R^3 , R^{3a} , and R^{3b} are as defined above;

and

 R^2 is $-N-R^{10}$ wherein R^{10} is hydrogen and

5

 R^{11} is $-(CH_2)_m N-R^5$ wherein m , R^5 , and R^6 are as defined above,wherein n , R^5 , R^6 are as

10

defined above.

Particularly valuable in the first aspect of the present invention is a compound selected from the group consisting of:


- N-(1-Azabicyclo[2.2.2]octan-3-yl)-3-(2-pyridinyl)-2-quinoxalinamine;
- N-[3-(1H-Imidazol-1-yl)propyl]-3-(2-pyridinyl)-2-quinoxalinamine;
- 15 N-[2-(1-Methyl-2-pyrrolidinyl)ethyl]-3-(2-pyridinyl)-2-quinoxalinamine;
- 1-[3-[[3-Pyridinyl)-2-quinoxalinamine]amino]propyl]-2-pyrrolidinone;
- N-[4-(4-Morpholinyl)phenyl]-3-(2-pyridinyl)-2-quinoxalinamine;
- N-(4-Piperidinylmethyl)-3-(2-pyridinyl)-2-quinoxalinamine;
- N-[4-(Dimethylamino)phenyl]-3-(2-pyridinyl)-2-quinoxalinamine;
- 20 N-Methyl-N-[4-[[3-(2-pyridinyl)-2-quinoxalinyl]amino]phenyl]-acetamide;
- N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N',N'-dimethyl-cyclohexane-1,4-diamine;
- N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-cyclohexane-1,4-
- 25 diamine;
- 2-[1,4']Bipiperidinyl-1'-yl-6,7-dichloro-3-pyridin-2-yl-quinoxaline;
- (6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(4-diethylaminomethyl-phenyl)-amine;

-43-




N'-(6,7-Dichloro-3-furan-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-diamine;

N'-(6,7-Dichloro-3-thiophen-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-diamine;

5





N'-(6,7-Difluoro-3-thiophen-2-yl-quinoxalin-2-yl)-N,N-dimethyl-butane-1,4-diamine;




10

-44-




N'-[6,7-Dichloro-3-(1H-indol-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;



5

N'-(3-Benzo[b]thiophen-2-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;







10

N,N-Diethyl-N'-(3-thiophen-2-yl-7-trifluoromethyl-quinoxalin-2-yl)-butane-1,4-diamine;

N'-[6,7-Dichloro-3-(5-methyl-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;

-45-



5 N'-(6,7-Dichloro-3-thiazol-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-diamine;

N'-(3-[2,2']Bithiophenyl-5-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;


10 N'-[6,7-Dichloro-3-(5-chloro-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;

N'-[6,7-Dichloro-3-(5-methoxy-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;


N'-[6,7-Dichloro-3-(5-propyl-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;

-46-

N'-(3-Benzofuran-2-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;





5 N'-[6,7-Dichloro-3-dibenzothiophen-4-yl-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;




[6,7-Dichloro-3-(5-phenyl-oxazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

10 [6,7-Dichloro-3-(5-thiophen-2-yl-oxazol)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;



-47-



N-(6,7-Dichloro-3-pyridin-3-yl-quinoxalin-2-yl)-N',N'-dimethyl-
cyclohexane-1,4-diamine;

5 N-(6,7-Dichloro-3-pyridin-4-yl-quinoxalin-2-yl)-N',N'-dimethyl-
cyclohexane-1,4-diamine;

N-(6,7-Dimethoxy-3-pyridin-2-yl-quinoxalin-2-yl)-N',N'-dimethyl-
cyclohexane-1,4-diamine;

10 N,N-Dimethyl-N'-(3-pyridin-2-yl-7,8-dihydro-6H-
cyclopenta[g]quinoxalin-2-yl)-cyclohexane-1,4-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-ethane-
1,2-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-
1,3-diamine;

15 N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-butane-
1,4-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-pentane-
1,5-diamine;

N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-pentane-1,5-diamine;

20 N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-hexane-
1,6-diamine;

[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylsulfanyl)-propyl]-
dimethylamine;

-48-

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(3-morpholin-4-yl-propyl)-amine;

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(3-methoxypropyl)-amine;

N'-1-[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylamino)-propyl]-N'-1-

5 methyl-propane-1,3-diamine;

2-{[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylamino)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol;

{4-[4-(2-Chloro-phenyl)-piperidin-1-yl]-butyl-(6,7-dichloro-3-pyridin-2-yl-quinoxalin-2-yl)} amine;

10 (6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(1-phenyl-4-piperidin-1-yl-butyl)-amine;

[6,7-Dichloro-3-(1-ethyl-5-phenyl-imidazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;


15 [6,7-Dichloro-3-(1-phenyl-imidazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

[6,7-Dichloro-3-[1-ethyl-5-(5-methyl-thiophene-2-yl)-imidazol-5-yl]-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine; and

[6,7-Dichloro-3-(1-phenyl-pyrazolo-5-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

20 or a pharmaceutically acceptable salt thereof.

A preferred compound of Formula II in the second aspect of the present invention is one wherein A is selected from the group consisting of:



wherein R^3 , R^{3a} , and R^{3b} are each independently the same or

different and are hydrogen,

25 alkyl,

aryl,


heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

alkyl,

-49-

aryl,
aralkyl,
acetyl, or




5

R^5 and R^6 are each the same or different and are hydrogen,
alkyl, cycloalkyl, acetyl, or

R^5 and R^6 are taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or $\text{N}-\text{R}^4$ wherein R^4 is as defined above and
m is an integer of 2 to 5,


10



15


each independently the same or different and are hydrogen,
alkyl,
aryl,
aralkyl,
acetyl, or

20




25

above or R^7 and R^8 taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or $\text{N}-\text{R}^4$ wherein R^4 and m are as defined
above,



30



-50-

$-(CH_2)_n-SO_2OR^4$ wherein R^4 and n are as defined above,

$-(CH_2)_n-CO_2R^4$ wherein R^4 and n are as defined above,

$-CH_2OR^4$ wherein R^4 is as defined above,


halogen,

5 CF_3 ,

CBr_3 ,


CCl_3 , or

NO_2 ,




wherein R^3 and R^{3a} are as defined above,


10




wherein R^3 and R^{3a} are as defined above,




wherein R^3 and R^{3a} are as defined above, or



wherein R^3 and R^{3a} are as defined above;







wherein R^3 , R^{3a} , and R^{3b} are as defined above,







wherein R^3 , R^{3a} , and R^{3b} are as defined above,


-51-










5



-52-




wherein R³, R^{3a}, and R^{3b} are as defined

above,

wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined above,

5

-53-



halogen, or
alkoxy; and

R^{2a} is CF_3 ,

CCl_3 ,


CBr_3 , or

$-N-R^{10}$ wherein R^{10} is hydrogen and

$|$
 R^{11}


R^{11} is $-(CH_2)_mN-R^5$ wherein m , R^5 , and R^6 are as defined above,

$|$
 R^6



defined above.

A more preferred compound of Formula II in the second aspect of the present invention is one wherein A is



different and are hydrogen,

-54-

alkyl,

aryl,

heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

5

alkyl,

aryl,

aralkyl,

acetyl, or

10

$$-(\text{CH}_2)_m-\text{N}-\text{R}^5 \text{ wherein}$$

$$\quad \quad \quad |$$

$$\quad \quad \quad \text{R}^6$$

R⁵ and R⁶ are each the same or different and are hydrogen,
alkyl, cycloalkyl, acetyl, or

15

R⁵ and R⁶ are taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or N-R⁴ wherein R⁴ is as defined above and
m is an integer of 2 to 5,

$$-(\text{CH}_2)_n-\text{N}-\text{R}^7 \text{ wherein } n \text{ is zero or an integer of 1 and } \text{R}^7 \text{ and } \text{R}^8 \text{ are}$$

$$\quad \quad \quad |$$

$$\quad \quad \quad \text{R}^8$$

20

each independently the same or different and are hydrogen,

alkyl,

aryl,

aralkyl,

25

acetyl, or

$$-(\text{CH}_2)_m-\text{N}-\text{R}^5 \text{ wherein } \text{R}^5 \text{ and } \text{R}^6 \text{ are as defined}$$

$$\quad \quad \quad |$$

$$\quad \quad \quad \text{R}^6$$

30

above or R⁷ and R⁸ taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or N-R⁴ wherein R⁴ and m are as defined
above,

-55-

-(CH₂)_n-CON-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂N-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂OR⁴ wherein R⁴ and n are as defined above,

-(CH₂)_n-CO₂R⁴ wherein R⁴ and n are as defined above,

-CH₂OR⁴ wherein R⁴ is as defined above,

halogen,


CF₃,

CBr₃,


CCl₃, or

NO₂;


15

R^{1a} is


wherein R³, R^{3a}, and R^{3b} are as defined above,



wherein R³, R^{3a}, and R^{3b} are as defined above,








wherein R³, R^{3a}, and R^{3b} are as defined above,




wherein R³, R^{3a}, and R^{3b} are as defined above,

-56-



or



R^{2a} is CF_3 ,

CCl_3 ,

10 CBr_3 , or


$-N-R^{10}$ wherein R^{10} is hydrogen and

|
 R^{11}

15 R^{11} is $-(CH_2)_m-N-R^5$ wherein m , R^5 , R^6 are as defined above, or


|
 R^6

-57-



above.

Another more preferred compound of Formula II in the second aspect of the present invention is one wherein



or different and are hydrogen,

alkyl,

aryl,

heteroaryl,

10 $-\text{OR}^4$ wherein R^4 is hydrogen,

alkyl,

aryl,

aralkyl,

acetyl, or

15 $-(\text{CH}_2)_m-\text{N}(\text{R}^5)(\text{R}^6)$ wherein

R^5 and R^6 are each the same or different and are hydrogen, alkyl, cycloalkyl, acetyl, or

20 R^5 and R^6 are taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or $\text{N}-\text{R}^4$ wherein R^4 is as defined above and m is an integer of 2 to 5,

25 $-(\text{CH}_2)_n-\text{N}(\text{R}^7)(\text{R}^8)$ wherein n is zero or an integer of 1 and R^7 and R^8 are

each independently the same or different and are hydrogen,

-58-

alkyl,
aryl,
aralkyl,
acetyl, or

5

$-(\text{CH}_2)_m\text{-N-R}^5$ wherein R^5 and R^6 are as defined
|
 R^6

above or

10

R^7 and R^8 taken together to form a 5- to
7-membered ring optionally containing an oxygen
atom or N-R^4 wherein R^4 and m are as defined
above,

15

$-(\text{CH}_2)_n\text{-CON-R}^7$ wherein R^7 , R^8 , and n are as defined above,
|
 R^8

$-(\text{CH}_2)_n\text{-SO}_2\text{N-R}^7$ wherein R^7 , R^8 , and n are as defined above,
|
 R^8

20

$-(\text{CH}_2)_n\text{-SO}_2\text{OR}^4$ wherein R^4 and n are as defined above,

$-(\text{CH}_2)_n\text{-CO}_2\text{R}^4$ wherein R^4 and n are as defined above,

$-\text{CH}_2\text{OR}^4$ wherein R^4 is as defined above,

halogen,


CF_3 ,

CBr_3 ,

25







CCl_3 , or

NO_2 ;



wherein R^3 , R^{3a} , and R^{3b} are as defined above,

-59-



R^{2a} is CF_3 ,

CCl_3 ,

CBr_3 , or


10 $-N-R^{10}$ wherein R^{10} is hydrogen and
 $|$
 R^{11}

R^{11} is $-(CH_2)_m-N-R^5$ wherein m , R^5 , and R^6 are as defined

15 $|$
 R^6


above,

-60-



defined above.

A most preferred compound of Formula II in the second aspect of the present invention is one wherein



or different and are hydrogen,

alkyl,

aryl,

heteroaryl,

10 $-\text{OR}^4$ wherein R^4 is hydrogen,

alkyl,

aryl,

aralkyl,

acetyl, or

15 $-(\text{CH}_2)_m-\text{N}-\text{R}^5$ wherein
 R^6

 R^5 and R^6 are each the same or different and are hydrogen,

alkyl, cycloalkyl, acetyl, or

20 R^5 and R^6 are taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or $\text{N}-\text{R}^4$ wherein R^4 is as defined above and m is an integer of 2 to 5,

25 $-(\text{CH}_2)_n-\text{N}-\text{R}^7$ wherein n is zero or an integer of 1 and R^7 and R^8 are
 R^8

each independently the same or different and are hydrogen,

-61-

alkyl,
aryl,
aralkyl,
acetyl, or

5 $-(CH_2)_m-N-R^5$ wherein R^5 and R^6 are as defined
|
 R^6

above or R^7 and R^8 taken together to form a 5- to
7-membered ring optionally containing an oxygen
10 atom or $N-R^4$ wherein R^4 and m are as defined
above,

$-(CH_2)_n-CON-R^7$ wherein R^7 , R^8 , and n are as defined above,
|
 R^8

15 $-(CH_2)_n-SO_2N-R^7$ wherein R^7 , R^8 , and n are as defined above,
|
 R^8

$-(CH_2)_n-SO_2OR^4$ wherein R^4 and n are as defined above,

$-(CH_2)_n-CO_2R^4$ wherein R^4 and n are as defined above,

20 $-CH_2OR^4$ wherein R^4 is as defined above,



halogen,

CF_3 ,




CBr_3 ,

CCl_3 , or


25 NO_2 ;






-62-



or



and



R^6 are as defined above.

Particularly valuable in the second aspect of the present invention is a compound selected from the group consisting of:

N'-[6-Chloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-diethyl-1,2-ethanediamine;


N'-[7-Chloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-diethyl-1,2-ethanediamine;

-63-

- N'-[6,7-Dichloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-diethyl-
1,2-ethanediamine;
6,7-Dichloro-3-(2-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-
2-quinoxalinamine;
- 5 6-Chloro-3-(2-pyridinyl)-N-[2-(1-pyrrolidinyl)ethyl]-2-quinoxalinamine;
7-Chloro-3-(2-pyridinyl)-N-[2-(1-pyrrolidinyl)ethyl]-2-quinoxalinamine;
N'-[6,7-Dimethyl-3-(2-pyridinyl)-2-quinoxaliny]-N,N-diethyl-
1,2-ethanediamine;
6-Chloro-3-(2-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-2-quinoxalinamine;
- 10 7-Chloro-3-(2-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-2-quinoxalinamine;
N'-[6,7-Dimethyl-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl-
1,3-propanediamine;
N'-[6-Chloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl-
1,3-propanediamine;
- 15 N'-[7-Chloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl-
1,3-propanediamine;
6-Chloro-N-[4-(dimethylamino)cyclohexyl]-3-(2-pyridinyl)-
2-quinoxalinamine;
7-Chloro-N-[4-(dimethylamino)cyclohexyl]-3-(2-pyridinyl)-
2-quinoxalinamine;
- 20 2,6,7-Trimethyl-3-piperazin-1-yl-quinoxaline;
N,N-Dimethyl-N'-(3-methyl-quinoxalin-2-yl)-propane-1,3-diamine;
2-Methyl-3-(4-methyl-piperazin-1-yl)-quinoxaline;
2-Ethyl-3-piperazin-1-yl-quinoxaline;
- 25 6,7-Dichloro-2-methyl-3-piperazin-1-yl-quinoxaline;
2-Phenyl-3-piperidin-1-yl-quinoxaline;
Benzyl-(3-phenyl-quinoxalin-2-yl)-amine;
Phenyl-(3-phenyl-quinoxalin-2-yl)-amine;
Methyl-(3-phenyl-quinoxalin-2-yl)-amine;
- 30 3-Phenyl-quinoxalin-2-ylamine;
2-Methyl-3-piperazin-1-yl-quinoxaline;
2-Methyl-3-piperidino-quinoxaline;




-64-

- 5-[4-(3-Methyl-quinoxalin-2-yl)-piperazin-1-yl]-pentan-1-ol;
 N,N-Dimethyl-N'-(3-methyl-quinoxalin-2-yl)-ethane-1,2-diamine;
 N,N-Diethyl-N'-(3-methyl-quinoxalin-2-yl)-ethane-1,2-diamine;
 (3-Methyl-quinoxalin-2-yl)-(3-morpholin-4-yl-propyl)-amine;
 5 N,N-Dimethyl-N'-(3-phenyl-quinoxalin-2-yl)-propane-1,3-diamine;
 3-Phenyl-quinoxalin-2-ylamine;
 2-Methyl-3-pyrrolidin-1-yl-quinoxaline;
 N-(1-Azabicyclo[2.2.2]octan-3-yl)-3-(2-pyridinyl)-2-quinoxalinamine;
 N-[3-(1H-Imidazol-1-yl)propyl]-3-(2-pyridinyl)-2-quinoxalinamine;
 10 N-[2-(1-Methyl-2-pyrrolidinyl)ethyl]-3-(2-pyridinyl)-2-quinoxalinamine;
 1-[3-[[3-Pyridinyl)-2-quinoxalinamine]amino]propyl]-2-pyrrolidinone;
 N-[4-(4-Morpholinyl)phenyl]-3-(2-pyridinyl)-2-quinoxalinamine;
 N-(4-Piperidinylmethyl)-3-(2-pyridinyl)-2-quinoxalinamine;
 N-[4-(Dimethylamino)phenyl]-3-(2-pyridinyl)-2-quinoxalinamine;
 15 N-Methyl-N-[4-[[3-(2-pyridinyl)-2-quinoxalanyl]amino]phenyl]-
 acetamide;
 N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N',N'-dimethyl-
 cyclohexane-1,4-diamine;
 N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-cyclohexane-1,4-
 20 diamine;
 2-[1,4']Bipiperidinyl-1'-yl-6,7-dichloro-3-pyridin-2-yl-quinoxaline;
 (6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(4-diethylaminomethyl-
 phenyl)-amine;
 N'-(6,7-Dichloro-3-furan-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-
 25 1,3-diamine;
 N'-(6,7-Dichloro-3-thiophen-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-
 1,3-diamine;





-65-

N'-(6,7-Difluoro-3-thiophen-2-yl-quinoxalin-2-yl)-N,N-dimethyl-butane-1,4-diamine;




5




-66-

N'-[6,7-Dichloro-3-(1H-indol-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;





5 N'-(3-Benzo[b]thiophen-2-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;





N,N-Diethyl-N'-(3-thiophen-2-yl-7-trifluoromethyl-quinoxalin-2-yl)-butane-1,4-diamine;

10 N'-[6,7-Dichloro-3-(5-methyl-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;



-67-



N'-(6,7-Dichloro-3-thiazol-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-diamine;


5 N'-(3-[2,2']Bithiophenyl-5-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;

N'-[6,7-Dichloro-3-(5-chloro-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;

10 N'-[6,7-Dichloro-3-(5-methoxy-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;


N'-[6,7-Dichloro-3-(5-propyl-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;

N'-(3-Benzofuran-2-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;



15 N'-[6,7-Dichloro-3-dibenzothiophen-4-yl-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;





-68-



[6,7-Dichloro-3-(5-phenyl-oxazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

[6,7-Dichloro-3-(5-thiophen-2-yl-oxazol)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

5



-69-

N-(6,7-Dichloro-3-pyridin-3-yl-quinoxalin-2-yl)-N',N'-dimethyl-cyclohexane-1,4-diamine;

N-(6,7-Dichloro-3-pyridin-4-yl-quinoxalin-2-yl)-N',N'-dimethyl-cyclohexane-1,4-diamine;

5 N-(6,7-Dimethoxy-3-pyridin-2-yl-quinoxalin-2-yl)-N',N'-dimethyl-cyclohexane-1,4-diamine;

N,N-Dimethyl-N'-(3-pyridin-2-yl-7,8-dihydro-6H-cyclopenta[g]quinoxalin-2-yl)-cyclohexane-1,4-diamine;

10 N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-ethane-1,2-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-butane-1,4-diamine;

15 N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-pentane-1,5-diamine;

N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-pentane-1,5-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-hexane-1,6-diamine;

20 [3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylsulfanyl)-propyl]-dimethylamine;

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(3-morpholin-4-yl-propyl)-amine;

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(3-methoxypropyl)-amine;

25 N'-1-[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylamino)-propyl]-N'-1-methyl-propane-1,3-diamine;

2-{{3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylamino)-propyl}-(2-hydroxy-ethyl)-amino}-ethanol;

30 {4-[4-(2-Chloro-phenyl)-piperidin-1-yl]-butyl-(6,7-dichloro-3-pyridin-2-yl-quinoxalin-2-yl)} amine;

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(1-phenyl-4-piperidin-1-yl-butyl)-amine;

-70-

[6,7-Dichloro-3-(1-ethyl-5-phenyl-imidazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

[6,7-Dichloro-3-(1-phenyl-imidazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

5 [6,7-Dichloro-3-[1-ethyl-5-(5-methyl-thiophene-2-yl)-imidazol-5-yl]-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine; and

[6,7-Dichloro-3-(1-phenyl-pyrazolo-5-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

or a pharmaceutically acceptable salt thereof.

10 The compounds of Formula I and II are valuable receptor antagonists of IL-8.

The IL-8 chemokine inhibitory effects of compounds of the present invention were determined by the following procedures:

Chemotaxis Assay

15 Compounds of Formula I and II were evaluated for their effect on chemotaxis using methodology known in the art, e.g., Carr M.W., Roth S.J., Luther E., Rose S.S., and Springer T.A., "Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant." *Proc. Natl. Acad. Sci. USA*, 1994;91:3652; Qin S., Larosa G., Campbell J.J. et al., "Expression of MCP-1 and
20 IL-8 receptors on subset on T-cells, and correlation with transendothelial chemotactic potential," *Eur. J. Immu.*, 1996;26:640.

Briefly, freshly isolated human neutrophils were resuspended in chemotaxis buffer, which is made of one part of RPMI 1640 medium, one part of Medium 199, and 0.5% BSA. The cells were incubated with or without
25 compounds for 5 minutes. Similarly, rhIL-8 was incubated in a separate plate, then transferred into lower chambers of chemotaxis plate. Neutrophils were added onto the top chamber. The plates were incubated at 37°C for 30 minutes. The top chamber was then removed and the plate frozen at -80°C for 30 minutes. After thawing, migrated cells were stained with Cytoquant Cell Proliferation Assay Kit
30 (Molecular Probes No. C-7026) and quantitated by reading the plate on a fluorescent plate reader.

-71-

Calcium Flux Assay

Compounds of Formula I and II were evaluated for their effect on calcium flux using methodology known in the art, e.g., Neote K., DiGregorio D., Mak J.Y., Horuk R., and Schall T.J., "Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor," *Cell*, 1993;72:415.

Briefly, human neutrophils were incubated with the fluorescence dye FLUO-3 for 1 hour. The cells were washed after this loading period, resuspended in HANKs buffer, and loaded into a 96-well plate. Compound was added to each well. After a 2-minute incubation period, the cells were stimulated with human IL-8 and the calcium flux response recorded and quantified.

The data in Table 1 shows the effect of a representative compound of the present invention on chemotaxis and calcium flux.

TABLE 1		
Example	IL-8 Chemotaxis (IC ₅₀ = μ M)	IL-8 Ca ⁺² Flux % Inhibition (μ M)
1	0.89	34% @ 11
14	1.8	
15	0.32	
25	0.31	
28	0.4	
34	0.08	

The compounds of Formula I and II may be obtained by applying synthetic methodology known in the art, such as, for example, Werbel L. et al., *J. Med. Chem.*, 1968;11:630; Moderhack D., et al., *Chem. Ber.*, 1994:1633; Loriga M, et al., *Farmaco*, 1995;50(5):289; *Chin. Chem. Lett.*, 1990;1(3):25; Shepard T. and Smith D.M., *J. Chem. Soc., Perkin Trans I*, 1987;3(501):11.

The procedures which may be used for the preparation of compounds 2 to 8 of Scheme 1 from compound 1 are described below.

Compounds of structure 4 in Scheme 1 are prepared by treating diamine 1 with the appropriate glyoxylate oxime in 20% to 40% H₂SO₄ at 50°C to 80°C for up to 2 days to give 2. Compound 3 is prepared by treatment of 2 with phosphorous oxychloride at reflux for up to 1 day. Treatment of 3 with two or more equivalents of the appropriate diamine in aromatic or ether solvents at reflux

-72-


for up to 3 days gives 4. If one equivalent of diamine is used, treatment of one equivalent of an organic base or K_2CO_3 in aromatic solvents at reflux for up to 3 days is used to prepare 4 from 3.

5 Compounds of structure 5 are prepared by treating 3 with two or more equivalents of the corresponding thiol or amine in aromatic solvents at reflux for up to 3 days. If the acid salt of the thiol or amine is used, one or two equivalents of an organic base in aromatic solvents or ethers at reflux for up to 3 days may be used to prepare 5 from 3.

10 Compounds of structure 7 or 8 are prepared by treating 3 with 2 equivalents of the corresponding protected amine in aromatic solvents at reflux for up to 3 days to give 6. Compound 7 is prepared from 6 by treatment with concentrated mineral acid or gaseous HCl in aromatic solvent or alcohols at 0° to room temperature for up to 1 day. Treatment of 7 with formalin and formic acid at 50°C to 100°C for up to 2 days gives 8.

-73-

Scheme 1



wherein Ar is Aryl or Pyridine and $n = 0$ to 6;

R = Alkyl, alkoxy, halogen, or H;


5 R₁ = Alkyl, aryl, or H;

R₂ = Alkyl, aryl, or H;

X = Sulfur, oxygen, nitrogen, N-Me.

-74-

Scheme 2



5 The procedure for the preparation of compound 2 to 8 of Scheme 2 are described below.

Compounds of structure 5 in Scheme 2 are prepared by treating diamine 1 with dialkyl oxalate at reflux (150-250°C) for up to 10 hours to give 2.

Compounds 3 are prepared upon treatment of 2 with a bromination reagent,

-75-

preferably PBr_5 at 100°C to 200°C for up to 3 hours. The dibromide 3 is dissolved in diethyl ether or THF solvent and treated with two or more equivalents of the diamine 6 at 0°C to room temperature for up to 5 hours to give compound 4.

Compounds of structure 5 are prepared by treating 4 with heterocyclic stannanes, 1-10% catalytic palladium catalyst, preferably $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$, with 2-20% copper salt, such as CuI at 50°C to 100°C . Additionally, compounds of structure 8 are prepared by reacting compounds 3 with ammonia followed by Stille-coupling reaction and alkylation as shown in Scheme 2.

The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or II or a corresponding pharmaceutically acceptable salt of a compound of Formula I or II.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium

-76-

carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged

-77-

preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

5 The quantity of active component in a unit dose preparation may be varied or adjusted from 1 mg to 1000 mg, preferably 10 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

10 In therapeutic use as agents for the treatment of psoriasis, or atopic dermatitis, disease associated with pathological angiogenesis (i.e., cancer), asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, 15 or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases, the compounds utilized in the pharmaceutical method of this invention can be administered at the initial dosage of about 1 mg to about 100 mg per kilogram daily. A daily dose range of about 25 mg to about 75 mg per kilogram is preferred. The dosages, however, may be varied depending upon the 20 requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the 25 circumstance is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

 The following nonlimiting examples illustrate the inventors' preferred methods for preparing the compounds of the invention.


Synthesis of Intermediates

30

Intermediate a

6,7-Dichloro-1,4-dihydroquinoxaline-2,3-dione:


-78-



A mixture of 4,5-dichlorophenylenediamine (54 g, 305 mmol) and diethyl oxalate (124 mL, 146.1 g, 920 mmol) was refluxed overnight, cooled to room temperature, and filtered. The residue was washed with ethanol and dried in vacuo to give the title product as a gray solid powder (67.5 g, 96%); mp >320°C; IR (KBr, cm⁻¹) 3188, 3156, 3057, 2918, 1724, 1693, 1613, 1497, 1452, 1340, 1338, 1250, 1131, 877, 811, 676, 669, 565; ¹H NMR (DMSO) δ 12.00 (s, 2H), 7.18 (s, 2H); ¹³C NMR (DMSO) δ 154.8, 126.0, 124.4, 116.0; MS (ACPI), *m/z* 231.0 (M⁺); Anal. Calcd for C₈H₄N₂O₂Cl₂: C, 41.59; H, 1.75; N, 12.12. Found: C, 41.60; H, 1.85; N, 12.05.

Intermediate b

2,3-Dibromo-6,7-dichloroquinoxaline:




6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione (5.39 g, 23.3 mmol) and phosphorus pentabromide (20.1 g, 46.7 mmol) were charged in a 100 mL round-bottom flask equipped with a condenser with an outlet half immersed in 10% NaOH aqueous solution (to absorb HBr generated during the reaction). The reaction was heated at 155°C using an oil-bath for 2 hours when the formation of HBr ceased. The reaction content was poured into ice-water (100 mL) and basified with NH₄OH. After filtration, the solid was dried and recrystallized using EtOH to give the desired product as a white solid (7.84 g, 94% yield): mp 169-70°C; R_f = 0.50, CH₂Cl₂; IR (KBr, cm⁻¹) 3088, 1539, 1451, 1240, 1128, 964, 997; ¹H NMR (CDCl₃) δ 8.13 (s, 2H); ¹³C NMR (CDCl₃) δ 142.4, 139.7, 136.3; MS (ACPI), *m/z* 338.4 (MH⁺); Anal. Calcd for C₈H₂N₂Cl₂Br₂: C, 26.93; H, 0.56; N, 7.85. Found: C, 26.93; H, 0.56; N, 7.86.

-79-


Intermediate c

2-Bromo-3-amino-6,7-dichloroquinoxaline:



- 2,3-Dibromo-6,7-dichloro-quinoxaline (2.75 g, 7.7 mmol) was dissolved in DMF (50 mL). Anhydrous ammonia was bubbled into the solution. After 2 hours, DMF was removed in vacuo at 70°C. The residue was filtered through a pad of silica gel (one inch thick) eluted with ethyl acetate. After removal of the solvent in vacuo, the residue was recrystallized from acetone to give the desired 2-bromo-3-amino-6,7-dichloroquinoxaline as a white solid. (7.84 g, 89% yield): mp 232-4°C;
- $R_f = 0.41$, EtOAc:Hex (1:1); IR (KBr, cm^{-1}) 3488, 3348, 1617, 1588, 1443, 1406, 1338, 1114, 1036, 965, 893, 867, 577, 557; ^1H NMR (DMSO) δ 8.02 (s, 1H), 7.76 (s, 1H), 7.51 (broad s, 2H, NH_2), 7.18 (s, 2H); ^{13}C NMR (DMSO) δ 147.7, 136.7, 131.4, 129.0, 128.8, 124.4, 122.3, 121.9; MS (ACPI), m/z 291.8 (M-1) $^-$; Anal. Calcd for $\text{C}_8\text{H}_4\text{N}_3\text{BrCl}_2$: C, 32.80; H, 1.38; N, 14.34. Found: C, 32.98; H, 1.43; N, 14.34.

Intermediate d




- A 50 mL round-bottom flask was charged with 2-bromo-3-amino-6,7-dichloro-quinoxaline (1.03 g, 3.52 mmol), 1-benzenesulfonyl-2-tributylstannyl-1H-indole (2.30 g, 4.21 mmol), bis(triphenylphosphine)palladium (II) chloride (259 mg, 0.352 mmol), CuI (77 mg, 0.703 mmol), and THF (40 mL). The suspension was refluxed for 30 minutes, cooled to room temperature. Charcoal was added, and the reaction mixture was heated to boil and filtered through a pad of Celite (1 inch

-80-

thick). The filtrate was concentrated in vacuo, and the residue was chromatographed using neutral alumina and eluting with 0-5% CH₃OH/EtOAc to give the desired product as a yellow solid (1.51 g, yield 92%): mp 129-132°C; R_f = 0.26, EtOAc:Hex (1:1); ¹H NMR (DMSO) δ 8.14 (s, 1H), 8.03 (d, J=8.4 Hz, 1H), 7.86 (d, J=1.6 Hz, 1H), 7.84 (d, 1H), 7.63 (m, 4H), 7.43 (dt, J₁=7.32, 1.1 Hz, 1H), 7.31 (dt, J=7.32, 0.9 Hz, 1H), 7.17 (broad s, 2H); ¹³C NMR (DMSO) δ 153.6, 141.8, 141.1, 136.7, 136.4, 134.7, 134.6, 134.3, 132.8, 130.0, 129.6, 129.4, 126.9, 125.9, 125.7, 125.6, 124.2, 122.0, 114.7; MS (ACPI), *m/z* 469.0.0 (M⁺+1), 471.0 (M⁺+2); Anal. Calcd for C₂₂H₁₄N₄Cl₂O₂S₁: C, 56.30; H, 3.01; N, 11.94. Found: C, 56.22; H, 3.04; N, 11.82.

Intermediate e

2-Amino-3-(2-furanyl)-6,7-dichloroquinoxaline:




The title compound was prepared according to the experimental procedure for Intermediate d and was obtained as a yellow crystalline solid (yield 84%): mp 222-223°C; R_f = 0.26, EtOAc:Hex (1:1); ¹H NMR (DMSO) 8.14 (s, 1H), 8.03 (d, J=8.4 Hz, 1H), 7.86 (d, J=1.6 Hz, 1H), 7.84 (d, 1H), 7.63 (m, 4H), 7.43 (dt, J₁=1.1 Hz, J₂=7.32 Hz, 1H), 7.31 (dt, J=6.77, 0.9 Hz, 1H), 7.17 (broad s, 2H); ¹³C NMR (DMSO) δ 153.6, 141.8, 141.1, 136.7, 136.4, 134.7, 134.6, 134.3, 132.8, 130.0, 129.6, 129.4, 126.9, 125.9, 125.7, 125.6, 124.2, 122.0, 114.7; MS (ACPI), *m/z* 469.0.0 (M⁺+1), 471.0 (M⁺+2); Anal. Calcd for C₂₂H₁₄N₄Cl₂O₂S₁: C, 56.30; H, 3.01; N, 11.94. Found: C, 56.22; H, 3.04; N, 11.82.

Intermediate f

2-Amino-3-(2-thiophenyl)-6,7-dichloroquinoxaline:

-81-




The title compound was prepared according to the experimental procedure for Intermediate d and was obtained as a yellow crystalline solid (yield 77%):

mp 235-237°C; R_f = 0.17, EtOAc:Hex (1:2); IR (KBr, cm^{-1}) 3472, 3311, 1614,

5 1588, 1463, 1432, 1404, 1351, 1329, 1227, 1110, 948, 879, 849, 728, 597; ^1H NMR (DMSO) 7.19 (broad s, 1H), 7.24 (dd, J =5.1, 3.8 Hz, 1H), 7.72 (s, 1H), 7.83 (dd, J =5.1, 0.9 Hz, 1H), 7.94 (dd, J =5.1, 0.9 Hz, 1H), 7.96 (s, 1H); ^{13}C NMR (DMSO) δ 151.1, 140.4, 140.3, 140.2, 135.3, 131.7, 130.8, 128.8, 126.2, 125.6; MS (ACPI), m/z 295.9 (M^+), 293.9 (M^+-2); Anal. Calcd for $\text{C}_{12}\text{H}_7\text{N}_3\text{Cl}_2\text{S}_1$: C, 48.66; H, 2.38; N, 14.19. Found: C, 48.74; H, 2.58; N, 14.06.

Intermediate g

2-Amino-3-(2-thiazole)-6,7-dichloroquinoxaline:



The title compound was prepared according to the experimental procedure for Intermediate d and was obtained as a bright yellow crystalline solid (yield 81%):

mp 219-221°C; R_f = 0.19, EtOAc:Hex (1:2); IR (KBr, cm^{-1}) 3426, 3363, 3320,


3200, 1624, 1459, 1341, 1235, 1208, 1109, 953, 884, 812, 462; ^1H NMR (DMSO)

7.29 (broad s, 1H), 7.79 (s, 1H), 8.05 (s, 1H), 8.67 (s, 1H), 9.31 (s, 1H); ^{13}C NMR (DMSO) δ 158.0, 151.4, 143.8, 140.4, 139.2, 135.7, 132.4, 128.8, 126.5,

125.8; MS (ACPI), m/z 296.9 (M^++1), 298.9 (M^++2); Anal. Calcd for $\text{C}_{11}\text{H}_6\text{N}_4\text{Cl}_2\text{S}_1$: C, 44.46; H, 2.04; N, 18.85. Found: C, 44.39; H, 2.10; N, 18.56.


-82-

Intermediate h



To a solution of 2,3-dibromo-6,7-dichloroquinoline (intermediate b) (10.35 g, 29.0 mmol) in THF (100 mL), 4-(diethylamino) butyl amine (8.35 g, 58.0 mmol) was added at room temperature. After 30 minutes, the reaction mixture was filtered to remove the precipitate. After the removal of the solvent in vacuo, the residue was chromatographed using silica gel, eluted with 2.5% Et₃N, 2.5% MeOH, 95% EtOAc, to give the desired product as a orange-yellow oil (12.18 g, 100%): ¹H NMR (CDCl₃) 1.03 (t, J=7.14 Hz), 1.61 (m, 2H), 1.72 (m, 2H), 2.52 (m, 6H), 3.56 (m, 2H), 5.96 (t, J=4.94 Hz), 7.79 (s, 1H), 7.87 (s, 1H); Anal. Calcd for C₁₆H₂₁N₄BrCl₂: C, 42.08; H, 4.86; N, 12.27; Found: C, 42.09; H, 4.79; N, 11.88.

Intermediate i



To a solution of 2,3-dibromo-6,7-dichloroquinoline (intermediate b) (10.4 g, 29.1 mmol) in THF (100 mL), 4-(dimethylamino) butyl amine (5.2 g, 44.8 mmol) was added at room temperature. After 30 minutes, the reaction mixture was filtered to remove the precipitate. After the removal of the solvent in vacuo, the residue was chromatographed using silica gel, eluted with 2.5% Et₃N, 2.5% MeOH, 95% EtOAc, to give the desired product as a orange-yellow oil (11.40 g, 100%).

EXAMPLE 1

6-Chloro-N-[4-(dimethylamino)cyclohexyl]-3-(2-pyridinyl)-2-quinoxalinamine
and 7-Chloro-N-[4-(dimethylamino)cyclohexyl]-3-(2-pyridinyl)-

-83-

2-quinoxalinamine, dihydrochloride, hydrate; mp 151-153°C (Werbel et al.,
J. Med. Chem., 1968;11:630).

EXAMPLE 2

5 N-(1-Azabicyclo[2.2.2]octan-3-yl)-3-(2-pyridinyl)-2-quinoxalinamine;
mp 63-65°C.

EXAMPLE 3

N-[3-(1H-Imidazol-1-yl)propyl]-3-(2-pyridinyl)-2-quinoxalinamine; mp 85-86°C.

EXAMPLE 4

10 N-[2-(1-Methyl-2-pyrrolidinyl)ethyl]-3-(2-pyridinyl)-2-quinoxalinamine;
mp 186-188°C.

EXAMPLE 5

1-[3-[[3-Pyridinyl)-2-quinoxalinamine]amino]propyl]-2-pyrrolidinone; pale amber
viscous liquid.

EXAMPLE 6

15 N-[4-(4-Morpholinyl)phenyl]-3-(2-pyridinyl)-2-quinoxalinamine; mp 205-206°C.

EXAMPLE 7

N-(4-Pyridinylmethyl)-3-(2-pyridinyl)-2-quinoxalinamine; mp 142-144°C.

EXAMPLE 8

20 N-[4-(Dimethylamino)phenyl]-3-(2-pyridinyl)-2-quinoxalinamine; mp
169-170°C.


EXAMPLE 9

N-Methyl-N-[4-[[3-(2-pyridinyl)-2-quinoxaliny]amino]phenyl]-acetamide;
mp 165-166°C.

-84-

EXAMPLE 10

N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N',N'-dimethyl-cyclohexane-1,4-diamine




5 The title compound was prepared according to the experimental procedure for Example 1 and was obtained as a yellow solid (84% yield); mp 180-182°C; ¹H NMR (DMSO) δ 1.80-2.45 (m, 8H), 2.92 (s, 6H), 4.58 (broad s, 1H), 7.80 (m, 1H), 7.75 (s, 1H), 8.07 (s, 1H), 8.10 (m, 1H), 8.82 (m, 1H); ¹Anal. Calcd for C₂₁H₂₃N₅Cl₂·1.0HCl: C, 55.70; H, 5.34; N, 15.47. Found: C, 55.52; H, 5.22; N, 15.42.

10

EXAMPLE 11

N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-cyclohexane-1,4-diamine




15 The title compound was prepared according to the experimental procedure for Example 1 following removal of BOC protecting group with HCl and was obtained as a yellow solid (98% yield); mp 280-282°C (dec.); ¹H NMR (DMSO) δ 1.82 (m, 4H), 2.22 (m, 2H), 2.46 (m, 2H), 4.38 (broad, s, 1H), 7.74 (dd, J₁=7.0,

-85-

4.7 Hz, 1H), 8.21 (dd, J=15.0, 7.0 Hz, 1H), 8.82 (dd, J=8.0, 4.0 Hz, 1 H); ¹Anal. Calcd for C₁₉H₁₉N₅Cl₂·2.0HCl: C, 49.48; H, 4.59; N, 15.18. Found: C, 49.03; H, 4.64; N, 14.98.

EXAMPLE 12


5 2-[1,4']Bipiperidiny1-1'-yl-6,7-dichloro-3-pyridin-2-yl-quinoxaline

The title compound was prepared according to the experimental procedure for Example 1 and was obtained as a bright yellow solid (92%); mp 275-277°C (dec.);

¹H NMR (CDCl₃) δ 1.33-1.82 (m, 12H), 2.48 (s, 3H), 2.75 (t, J=12.7 Hz, 2 H),
 10 7.35 (t, J=6.1 Hz, 1H), 7.87 (s, 1H), 7.37 (m, 1H), 8.06 (s, 1H), 8.76 (s, 1H); Anal. Calcd for C₂₃H₂₅N₅Cl₂·1.32HCl: C, 56.32; H, 5.41; N, 14.28. Found: C, 56.33; H, 5.36; N, 14.07.

EXAMPLE 13


15 (6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(4-diethylaminomethyl-phenyl)-amine



-86-

The title compound was prepared according to the experimental procedure for Example 1 and was obtained as an orange powder (83%); mp 250-252°C (dec.);
¹H NMR (CDCl₃) δ 1.04 (t, J=7.1 Hz, 6H), 2.57 (q, J=7.1 Hz, 4H), 3.61 (s, 2H),
 7.38 (d, J=8.4 Hz, 2H), 7.48 (dd, J=5.0, 1.0 Hz, 1H), 7.93 (s, 1H), 7.90 (s, 2H),
 7.97 (dt, J=8.1, 2.0 Hz, 1H), 8.03 (s, 1H), 8.73 (d, J=4.8 Hz, 1H), 8.84 (d,
 J=8.1 Hz, 1H), 12.87 (s, 1H); Anal. Calcd for C₂₄H₂₃N₅Cl₂·0.42 H₂O: C, 62.67;
 H, 5.22; N, 15.23. Found: C, 62.70; H, 5.05; N, 15.04.

EXAMPLE 14



10 N'-(6,7-Dichloro-3-furan-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-
diamine


To a solution of NaH (150 mg, 60% in mineral oil, 3.75 mmol) in DMF (10 mL) was added quinoxaline amine intermediate e (420 mg, 1.50 mmol) and 3-dimethylaminopropyl chloride hydrochloride (237 mg, 1.5 mmol). The reaction was heated at 80°C for 2 hours, cooled to room temperature. After removal of DMF in vacuo, the residue was chromatographed using neutral alumina eluted with 5-15% CH₃OH/EtOAc to give the desired product as a dark-yellow solid (94 mg, yield 60%); as a bis-HCl salt was obtained as a yellow solid by bubbling HCl gas into its EtOAc solution; mp 175-177°C.

20

EXAMPLE 15


N'-(6,7-Dichloro-3-thiophen-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-
diamine

-87-



The title compound was prepared according to the experimental procedure for Example 14 using Intermediate f and was obtained as a bis-HCl salt; mp 220-223°C; ¹H NMR (DMSO) δ 2.10 (m, 2H), 2.73 (δ, J=4.8 Hz, 6H), 3.13 (m, 2H), 3.60 (m, 2H), 7.28 (dd, J₁=5.1 Hz, J₂=3.7 Hz, 1H), 7.58 (broad t, 1H, NH), 7.86 (s, 1H), 7.88 (d, J=5.1, 1.0 Hz, 1H), 7.98 (dd, J=4.0, 1.0 Hz, 1H), 8.00 (s, 1H), 10.80 (broad s, 1H); Anal. Calcd for C₁₇H₁₈N₄Cl₂O: C, 46.60; H, 4.60; N, 12.79. Found: C, 46.62; H, 4.62; N, 12.57.

EXAMPLE 16




The quinoxaline bromide Intermediate i (890 mg, 2.27 mmol) was dissolved in THF (30 mL). To this solution was added tributylstannyl-2-furan (1.05 g, 2.95 mmol), PdCl₂.(PPh₃)₂ (80 mg, 0.113 mmol), and CuI (25 mg, 0.23 mmol). The resulting suspension was refluxed for 2 hours, cooled to room temperature, and filtered. The volatiles were removed in vacuo, and the residue was chromatographed using silica gel eluting with 5% Et₃N and 5% CH₃OH in EtOAc to give the desired product as a viscous oil. The bis HCl salt was prepared by bubbling HCl gas into the EtOAc solution of the free base; mp 247-248°C.

-88-


EXAMPLE 17

N'-(6,7-Difluoro-3-thiophen-2-yl-quinoxalin-2-yl)-N,N-dimethyl-butane-1,4-diamine



- 5 The title compound was prepared according to the experimental procedure for Example 16, and the free base was obtained as a yellow solid; mp 175-177°C; ^1H NMR (DMSO) δ , 1.60-1.80 (m, 4H), 2.19 (s, 6H), 2.36 (t, $J=7.0$ Hz, 2H), 3.55 (q, $J=6.5$ Hz, 2H), 6.12 (broad s, 1H), 7.18 (dd, $J_1=5.0$, 3.9 Hz, 1H), 7.42 (dd, $J=11.4$, 8.0 Hz, 1H), 7.54 (dd, $J=5.1$, 0.9 Hz, 1H), 7.61 (dd, $J=11.8$, 7.4 Hz, 1H), 7.68 (dd, $J=3.5$, 0.5 Hz, 1H); Anal. Calcd for $\text{C}_{18}\text{H}_{20}\text{N}_4\text{F}_2\text{S}\cdot 0.72\text{H}_2\text{O}$: C, 57.59; H, 5.76; N, 14.92. Found: C, 57.60; H, 5.44; N, 14.80.


EXAMPLE 18



- 15 The title compound was prepared according to the experimental procedure for Example 16, and the mono-citrate was obtained as a bright yellow powder; mp 110-112°C; ^1H NMR (DMSO) δ , 1.15 (t, $J=7.2$ Hz, 6H), 1.57 (m, 4H), 2.50 (q, $J=9.7$ Hz, 4H), 3.05 (m, 8H), 3.49 (q, $J=5.7$ Hz, 2H), 7.28 (dd, $J=5.1$, 3.9 Hz, 1H), 7.43 (t, $J=8.0$ Hz, 1H), 7.70 (t, $J=5.5$ Hz, 1H), 7.90 (ddd, $J=7.0$, 3.8, 0.9 Hz, 1H), 8.04 (ddd, $J=13.6$, 7.7, 1.3 Hz, 1H); Anal. Calcd for $\text{C}_{20}\text{H}_{24}\text{N}_5\text{O}_2\text{S}\cdot 1.0\text{C}_6\text{H}_8\text{O}_7\cdot 1.0\text{H}_2\text{O}$: C, 51.31; H, 5.63; N, 11.51. Found: C, 51.18; H, 5.43; N, 11.15.


-89-

EXAMPLE 19



Using the procedure of Example 15, 3-cyano propyl amine intermediate was obtained. The nitrile was subsequently treated with ethanolic HCl followed by ammonia in ethanol. The free base was converted to a TFA salt as a fluffy yellow powder; mp 106-108°C; ¹H NMR (DMSO) δ, All peaks are broad singlets, 2.01 (2H), 2.55 (5H), 3.52 (2H), 6.70 (1H), 7.40 (1H), 7.50 (1H), 7.78 (1H), 7.80 (1H), 8.74 (1H), 8.92 (1H).

EXAMPLE 20




10

The title compound was prepared from the corresponding nitrile according to the procedure of Example 19 and obtained as a brown waxy oil; ¹H NMR (CDCl₃) δ, All peaks are broad singlets, 1.98 (4H), 2.08 (2H), 2.66 (2H), 3.52 (4H), 3.64 (2H), 6.30 (1H), 7.16 (1H), 7.52 (1H), 7.70 (1H), 7.87 (1H), 7.90 (1H).


-90-

EXAMPLE 21



The title compound was prepared according to the experimental procedure for Example 16 using Intermediate h, and was obtained as a yellow-orange oil (quantitative yield). The compound was then dissolved in EtOAc, and HCl gas bubbled in to make the corresponding HCl salt. The salt was a yellow hygroscopic powder: Anal. Calcd for $C_{20}H_{24}N_4Cl_2S \cdot (2)HCl \cdot (1.24)H_2O$: C, 46.32; H, 5.51; N, 10.80. Found: C, 46.32; H, 5.55; N, 10.76.

EXAMPLE 22




The title compound was prepared according to the experimental procedure for Example 16 using Intermediate h, and was obtained as an orange oil (77%); 1H NMR ($CDCl_3$) 0.99 (t, $J=7.15$ Hz, 6H), 1.59 (m, 2H), 1.68 (m, 2H), 2.55 (m, 6H), 3.57 (dd, $J=12.45, 5.49$ Hz, 2H), 5.36 (broad t, $J=5.49$ Hz, 1H), 6.95 (d, $J=0.73$ Hz, 1H), 7.45 (m, 6H), 7.69 (s, 1H), 7.72 (s, 1H), 7.89 (s, 1H), 7.95 (s, 1H), 8.19 (dd, $J=8.33, 0.85$, 1H); MS (APCI), M/z 598.1 (M^++1), 599.1 (M^++2).

-91-

EXAMPLE 23

N'-[6,7-Dichloro-3-(1H-indol-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine




5 The title compound was prepared by refluxing a sodium hydroxide solution of Example 22 in methanol to remove the toluene sulfonamide protecting group, and the compound was obtained as a red-orange oil. The compound was then dissolved in EtOAc, and treated with HCl in EtOAc to form the HCl salt. The product is a brown-orange solid (98%); mp 145-147°C; Salt ¹H NMR (DMSO)

10 1.15 (broad t, J=6.8 Hz, 6H), 1.72 (broad s, 4H), 3.04 (broad s, 6H), 3.57 (broad s, 2H), 7.03 (t, J=7.32 Hz, 1H), 7.19 (t, J=7.78, 1H), 7.38 (broad s, 1H), 7.49 (d, J=8.05 Hz, 1H), 7.63 (d, J=7.81 Hz, 1H), 7.80 (s, 1H), 7.94 (s, 1H), 10.17 (broad s, 1H), 11.76 (s, 1H); Anal. Calcd for C₂₄H₂₇N₅Cl₂·(2)HCl·(1.58)H₂O: C, 51.68; H, 5.81; N, 12.56. Found: C, 51.68; H, 5.83; N, 12.45.

15

EXAMPLE 24



The title compound was prepared according to the experimental procedure for Example 16, and 2 regioisomers were obtained. The major product was obtained as an orange oil. The oil is dissolved in acetone and treated with 1 eq of

20 4-bromobenzoic acid and stored at 4°C for 24 hours to give the salt as a yellow solid (78%); mp 91-92°C; Free base ¹H NMR (CDCl₃) 1.00 (t, J=7.14 Hz, 3H), 1.59 (m, 2H), 1.73 (m, 2H), 2.49 (m, 6H), 3.61 (dd, J=12.12, 6.87 Hz, 2H), 6.09 (broad t, J=4.90 Hz, 1H), 7.21 (dd, J=5.13, 3.66 Hz, 1H), 7.59 (dd, J=5.13, 0.92 Hz, 1H), 7.69 (dd, J=3.66, 0.92 Hz, 1H), 7.78 (s, 1H), 8.203 (s, 1H); Anal.


-92-

Calcd for $C_{21}H_{24}N_4Cl_1F_3S \cdot (0.25)C_7H_5O_2Br$: C, 53.87; H, 5.02; N, 11.05;

Found: C, 53.72; H, 5.10; N, 11.20.


EXAMPLE 25

N'-(3-Benzo[b]thiophen-2-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-
1,4-diamine



The title compound was prepared according to the experimental procedure for Example 16 using Intermediate h, and was obtained as a yellow oil (99%); 1H NMR ($CDCl_3$) 0.99 (t, $J=7.14$ Hz, 6H), 1.61 (m, 2H), 1.75 (m, 2H), 2.49 (m, 6H), 3.61 (dd, $J=12.35, 6.84$ Hz, 2H), 6.00 (broad t, $J=5.13$ Hz, 1H), 7.43 (m, 2H), 7.81 (s, 1H), 7.86 (m, 2H), 7.92 (s, 1H), 7.99 (s, 1H); Anal. Calcd for $C_{24}H_{26}N_4Cl_2S \cdot (0.19)CHCl_3$: C, 58.56; H, 5.32; N, 11.29; Found: C, 58.52; H, 5.38; N, 11.19

EXAMPLE 26




The title compound was prepared according to the experimental procedure for Example 16, and 2 regioisomers were obtained. The major product was collected as an orange oil; 1H NMR ($CDCl_3$) 0.99 (t, $J=7.14$ Hz, 6H), 1.62 (m, 2H), 1.78 (m, 2H), 2.50 (m, 6H), 3.71 (dd, $J_1=12.37$ Hz, $J_2=6.86$ Hz, 2H), 6.21 (broad t, $J=4.86$ Hz, 1H), 7.21 (dd, $J=5.03, 3.75$ Hz, 1H), 7.61 (dd, $J=5.12, 1.10$ Hz, 1H), 7.73 (dd, $J=3.75, 0.92$ Hz, 1H), 7.82 (d, $J=1.64$ Hz, 1H), 8.08 (t, $J=0.97$ Hz, 1H);

-93-

Anal. Calcd for $C_{21}H_{24}N_4ClF_3S$: C, 55.20; H, 5.29; N, 12.26; Found: C, 55.22; H, 5.05; N, 11.77.

EXAMPLE 27


N,N-Diethyl-N'-(3-thiophen-2-yl-7-trifluoromethyl-quinoxalin-2-yl)-butane-1,4-
5 diamine



The title compound was prepared according to the experimental procedure for Example 16, and 2 regioisomers were obtained. The major product was collected as an orange oil (92.4%); 1H NMR ($CDCl_3$) 1.00 (t, $J=7.14$ Hz, 6H), 1.60 (m, 2H), 1.74 (m, 2H), 2.50 (m, 6H), 3.63 (m, 2H), 5.95 (broad s, 1H), 7.59 (t, $J=4.40$ Hz, 1H), 7.58 (d, $J=4.51$ Hz, 1H), 7.71 (m, 3H), 8.17 (s, 1H); Anal. Calcd for $C_{21}H_{25}N_4F_3S$: C, 59.70; H, 5.96; N, 13.26; Found: C, 60.56; H, 5.94; N, 13.00.

EXAMPLE 28

15 N'-[6,7-Dichloro-3-(5-methyl-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-
butane-1,4-diamine




The title compound was prepared according to the experimental procedure for Example 16 using Intermediate h, and the product was obtained as a yellow oil (95.1%); 1H NMR (DMSO) 0.89 (t, $J=7.14$ Hz, 6H), 1.45 (m, 2H), 1.64 (m, 2H), 2.48 (m, 2H), 2.51 (s, 3H), 3.44 (t, $J=6.23$ Hz, 2H), 6.95 (d, $J=3.66$ Hz, 1H), 7.27 (t, $J=5.31$ Hz, 1H), 7.69 (d, $J=3.66$ Hz, 1H), 7.73 (s, 1H), 7.91 (s, 1H); Anal.

-94-


Calcd for $C_{21}H_{26}N_4Cl_2S$: C, 57.66; H, 5.99; N, 12.81; Found: C, 57.44; H, 6.01; N, 12.40.

EXAMPLE 29



- 5 The title compound was prepared according to the experimental procedure for Example 16 using Intermediate h, and the product was obtained as a yellow-orange oil (79%); 1H NMR ($CDCl_3$) 1.03 (t, $J=7.08$ Hz, 6H), 1.59 (m, 2H), 1.68 (m, 2H), 2.52 (m, 6H), 3.52 (dt, $J=7.08, 5.37$ Hz, 2H), 4.26 (m, 2H), 4.31 (m, 2H), 6.73 (t, $J=5.37$ Hz, 1H), 7.15 (s, 1H), 7.70 (s, 1H), 7.80 (s, 1H); Anal. Calcd for $C_{20}H_{26}N_4Cl_2O_2 \cdot (0.06)H_2O$: C, 56.33; H, 6.16; N, 13.14; Found: C, 56.33; H, 6.15; N, 12.86.
- 10

EXAMPLE 30




- The title compound was prepared according to the experimental procedure for Example 16, and was obtained as a yellow-orange glass (90.2%); 1H NMR ($CDCl_3$) 0.99 (t, $J=7.08$ Hz, 6H), 1.59 (m, 2H), 1.69 (m, 2H), 2.51 (m, 4H), 3.63 (broad s, 2H), 5.59 (t, $J=5.20$, 1H), 6.95 (s, 1H), 7.32 (t, $J=7.56$, 1H), 7.39 (t, $J=7.81$ Hz, 1H), 7.44 (t, $J=7.81$ Hz, 1H), 7.55 (m, 6H), 7.69 (d, $J=8.24$ Hz, 1H), 7.79 (d, $J=8.79$ Hz, 1H), 8.02 (m, 4H), 8.17 (d, $J=8.30$ Hz, 1H), 8.50 (d,
- 15

-95-


J=1.95 Hz, 1H); Anal. Calcd for $C_{36}H_{37}N_5S_2O_4 \cdot (0.49)H_2O$: C, 63.90; H, 5.66; N, 10.35; Found: C, 63.91; H, 5.46; N, 9.98.

EXAMPLE 31



5 The title compound was prepared according to the experimental procedure for Example 16, and was obtained as a yellow-orange glass (99.2%); 1H NMR ($CDCl_3$) 1.00 (t, J=7.15 Hz, 6H), 1.61 (m, 2H), 1.71 (m, 2H), 2.51 (m, 6H), 3.62 (m, 2H), 6.10 (t, J=5.20 Hz, 1H), 7.20 (dd, J=5.13, 3.66 Hz, 1H), 7.52 (m, 3H), 7.59 (d, J=5.12 Hz, 1H), 7.69 (d, J=3.66 Hz, 1H), 7.71 (d, J=9.03 Hz, 1H),
10 8.00 (m, 3H), 8.51 (d, J=6.60 Hz, 1H); Anal. Calcd for $C_{26}H_{30}N_4S_2O_2$: C, 63.13; H, 6.11; N, 11.33; Found: C, 62.98; H, 6.08; N, 10.96.

EXAMPLE 32




The title compound was prepared according to the experimental procedure for
15 Example 16 using Intermediate h, and was obtained as a yellow-orange oil; 1H NMR ($CDCl_3$) 1.04 (m, 6H), 1.24 (m, 6H), 1.69 (m, 4H), 2.04 (m, 1H), 2.29 (m, 1H), 2.55 (m, 6H), 3.51 (m, 2H), 3.64 (m, 1H), 3.81 (m, 1H), 6.67 (s, 1H), 7.08 (s, 1H), 3.37 (broad t, J=4.59 Hz, 1H), 7.68 (s, 1H), 7.76 (s, 1H); Anal. Calcd for $C_{20}H_{28}N_4Cl_2O_1$: C, 58.39; H, 6.86; N, 13.62; Found: C, 58.49; H, 6.71; N,
20 13.28.

-96-

EXAMPLE 33


N'-(6,7-Dichloro-3-thiazol-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-diamine



- 5 The title compound was prepared according to the experimental procedure for Example 14 using Intermediate g, and the free base converted into the HCl salt by treating it with EtOAc·HCl (39.5%). The salt is a yellow solid; ¹H NMR (DMSO) 2.08 (m, 2H), 2.74 (d, J=4.95 Hz, 6H), 3.14 (m, 2H), 3.57 (m, 2H), 7.59 (m, 1H), 7.87 (s, 1H), 8.05 (s, 1H), 8.70 (s, 1H), 7.37 (s, 1H), 10.59 (broad s, 1H); Anal.
- 10 Calcd for C₁₆H₁₇N₅Cl₂S₁·(1.5)HCl: C, 44.14; H, 4.23; N, 16.02; Found: C, 44.14; H, 4.23; N, 16.02.

EXAMPLE 34

N'-(3-[2,2']Bithiophenyl-5-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine; mp ca 180°C




15

-97-

EXAMPLE 35


N'-[6,7-Dichloro-3-(5-chloro-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-
butane-1,4-diamine; mp 98-100°C



5


EXAMPLE 36

N'-[6,7-Dichloro-3-(5-methoxy-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-
butane-1,4-diamine; glass



EXAMPLE 37


10 N'-[6,7-Dichloro-3-(5-propyl-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-
butane-1,4-diamine; mp 165-167°C



-98-


EXAMPLE 38

N'-(3-Benzofuran-2-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-
diamine; mp 220°C



5

EXAMPLE 39




mp 132°C

EXAMPLE 40


N'-(6,7-Dichloro-3-dibenzothiophen-4-yl-quinoxalin-2-yl)-N,N-diethyl-butane-
1,4-diamine; mp 134-136°C

10



-99-


EXAMPLE 41



mp 260-262°C.

EXAMPLE 42

5 [6,7-Dichloro-3-(5-phenyl-oxazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine




A solution of aminoquinoxaline bromide (159 mg, 0.38 mmol) in anhydrous THF (10 mL) was treated with 5-phenyloxazole (73 mg, 0.5 mmol), PdCl₂(PPh₃)₂ (18 mg, 0.025 mol), CuI (10 mg, 0.05 mmol), and potassium acetate (74 mg, 0.75 mmol). The mixture was heated to reflux under argon for 24 hours. Volatiles were removed *in vacuo*, and the residue was chromatographed on silica gel eluting with 10% CH₃OH and 3% Et₃N in ethyl acetate to give the free base as a viscous oil (80 mg, 44%). The bis·HCl salt was prepared by treating the free base with methanolic HCl; ¹H NMR (free base, CDCl₃) δ 1.80 (m, 8H), 2.54 (m, 6H), 3.62 (m, 2H), 7.43 (m, 3H), 7.72 (s, 1H), 7.80 (m, 2H), 8.00 (s, 1H), 8.86 (broad t, 1H); Anal. Calcd for C₂₅H₂₅N₅OCl₂·2HCl·1.9H₂O: C, 50.93; H, 5.26; N, 11.87; Found: C, 51.13; H, 4.95; N, 11.52.

-100-

EXAMPLE 43

[6,7-Dichloro-3-(5-thiophen-2-yl-oxazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine




- 5 The title compound was prepared according to the experimental procedure for Example 42; ^1H NMR (free-base, CDCl_3) δ 1.80 (m, 8H), 2.53 (m, 6H), 3.61 (m, 2H), 7.12 (m, 1H), 7.33 (s, 1H), 7.40 (m, 1H), 7.52 (m, 1H), 7.70 (s, 1H), 7.98 (s, 1H), 8.76 (broad t, 1H); Anal. Calcd for: $\text{C}_{23}\text{H}_{23}\text{N}_5\text{OSCl}_2 \cdot 2\text{HCl} \cdot \text{H}_2\text{O}$; C, 47.59; H, 4.86; N, 12.06; Found: C, 47.23; H, 4.86; N, 11.86.

10

EXAMPLE 44

[6,7-Dichloro-3-(5-pyridin-2-yl-oxazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine




- 15 The title compound was prepared according to the experimental procedure for Example 42; ^1H NMR (free-base, CDCl_3) δ 1.80 (m, 8H), 2.54 (m, 6H), 3.68 (m, 2H), 7.30 (m, 1H), 7.80 (s, 1H), 7.84 (m, 1H), 7.92 (s, 1H), 7.98 (m, 1H), 8.07 (s, 1H), 8.69 (m, 1H), 8.91 (broad t, 1H); Anal. Calcd for: $\text{C}_{24}\text{H}_{24}\text{ON}_6\text{Cl}_2 \cdot 2\text{HCl}$; C, 51.81, H, 4.71, N, 15.10; Found: C, 51.66, H, 4.78; N, 14.90.

-101-

EXAMPLE 45

[6,7-Dichloro-3-(5-phenyl-thiophen-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine




- 5 The title compound was prepared according to the experimental procedure for Example 16; ^1H NMR (free-base, CDCl_3) δ 1.77 (m, 8H), 2.48 (m, 6H), 3.58 (m, 2H), 5.29 (broad t, 1H), 7.40 (m, 4H), 7.67 (m, 3H), 7.78 (s, 1H), 7.94 (s, 1H); Anal. Calcd for $\text{C}_{26}\text{H}_{26}\text{N}_4\text{S}\text{Cl}_2 \cdot 2\text{HCl} \cdot 1.5\text{H}_2\text{O}$: C, 52.27; H, 5.22; N, 9.37; Found: C, 52.47; H, 4.85; N, 9.05.

10

EXAMPLE 46

[6,7-Dichloro-3-(5-phenyl-thiophen-2-yl)-quinoxalin-2-yl]-N,N-dimethyl-butane-1,4-diamine




- 15 The title compound was prepared according to the experimental procedure for Example 16, using Intermediate i; ^1H NMR (free-base, CDCl_3) δ 1.65 (m, 2H), 1.76 (m, 2H), 2.13 (s, 6H), 2.30 (t, 2H), 3.54 (q, 2H), 6.43 (broad t, 1H), 7.38 (m, 4H), 7.65 (m, 3H), 7.74 (s, 1H), 7.91 (s, 1H); Anal. Calcd for:

-102-

$C_{24}H_{24}N_4SCl_2 \cdot 2HCl \cdot 0.25H_2O$: C, 52.51, H, 4.86, N, 10.20; Found: C, 52.45, H, 5.02; N, 10.06.

EXAMPLE 47

[6,7-Dichloro-3-methoxy-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine

5

A solution of aminoquinoxaline bromide (298 mg, 0.70 mmol) in anhydrous THF (10 mL) was treated with methanol (0.085 mL, 2.1 mmol), Et_3N (0.190 mL, 1.4 mmol), and $Ni(CO)_2(PPh_3)_2$ (575 mg, 0.9 mmol). The mixture was heated to reflux for 18 hours, followed by removal of the solvent *in vacuo*. The residue was chromatographed on silica gel eluting with 10% CH_3OH and 3% Et_3N in ethyl acetate to give the free base as a viscous oil (194 mg, 74%). The bis-HCl salt was prepared by treating the free base with methanolic HCl; 1H NMR (free-base, $CDCl_3$) δ 1.80 (m, 8H), 2.55 (m, 6H), 3.56 (m, 2H), 4.10 (s, 3H), 6.13 (broad s, 1H), 7.70 (m, 2H); Anal. Calcd for: $C_{17}H_{22}N_4OCl_2 \cdot 2HCl \cdot 2H_2O$: C, 42.69; H, 5.90; N, 11.71; Found: C, 42.70; H, 5.63; N, 11.60.

15

EXAMPLE 48

N-(6,7-Dichloro-3-pyridin-3-yl-quinoxalin-2-yl)-N',N'-dimethyl-cyclohexane-1,4-diamineStep (a): Preparation of: Ethyl 3-pyridylglyoxylate oxime

20

A solution of sodium ethoxide, which was prepared from metallic sodium (5.0 g) and absolute ethanol (70 mL), was added to anhydrous ethyl ether (300 mL). The resulting solution was placed under a nitrogen atmosphere and cooled in an ice-bath. Ethyl 3-pyridylacetate (35 g) was added to the solution and the resulting mixture stirred 15 minutes, then isoamyl nitrite (25 g) was added dropwise keeping the temperature of the reaction mixture between 5-10°C. After addition was complete, stirring was continued for 1 hour, water (100 mL) was added, and

25

-103-

the mixture was acidified with glacial acetic acid. After stirring 1 hour, the precipitate was filtered, washed with ethanol, and dried. Recrystallization from ethanol gave the product as a white solid (5.62 g); mp 162-164°C.

Step (b): Preparation of: 6,7-Dichloro-3-(3-pyridyl)-2-quinoxalinol

5 A solution of ethyl 3-pyridylglyoxylate oxime (3.35 g) and 4,5-dichlorophenylenediamine (3.05 g) in 35% sulfuric acid (75 mL) was stirred at 75°C for 17 hours. The solid, which formed on heating, was removed by filtration and triturated in water. Triturating in ethanol gave the product as a light brown solid (3.89 g).

10 Step (c): Preparation of: 2,6,7-Trichloro-3-pyridin-3-yl-quinoxaline

A slurry of 6,7-dichloro-3-(3-pyridyl)-2-quinoxalinol (3.5 g) in phosphorous oxychloride (35 mL) was refluxed for 6 hours. The resulting mixture was cooled, poured over ice, stirred 5 minutes, and made basic with concentrated NH₄OH.

15 The precipitate was removed by filtration and recrystallization in ethanol gave the product as white crystals (2.3 g); mp 174-175°C.

Step (d): Preparation of: N-(6,7-Dichloro-3-pyridin-3-yl-quinoxalin-2-yl)-N',N'-dimethyl-cyclohexane-1,4-diamine

A solution of 2,6,7-trichloro-3-pyridin-3-yl-quinoxaline (1.0 g) and N,N-dimethyl-cyclohexane-1,4-diamine in toluene (25 mL) was refluxed for 24 hours.

20 After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give the product as a yellow solid (0.43 g); mp 158-161°C.

EXAMPLE 49

25 N-(6,7-Dichloro-3-pyridin-4-yl-quinoxalin-2-yl)-N',N'-dimethyl-cyclohexane-1,4-diamine

-104-

Step (a): Preparation of: Ethyl 4-pyridylglyoxylate oxime

A solution of sodium ethoxide, which was prepared from metallic sodium (3.5 g) and absolute ethanol (50 mL), was added to anhydrous ethyl ether (200 mL). The resulting solution was placed under a nitrogen atmosphere and cooled in an ice-bath. Ethyl 4-pyridylacetate (25 g) was added to the solution and the resulting mixture stirred 15 minutes, then isoamyl nitrite (25 mL) was added dropwise keeping the temperature of the reaction mixture between 5-10°C. After addition was complete, stirring was continued for 1 hour, water (50 mL) was added, and the mixture was acidified with glacial acetic acid. After stirring 1 hour, the precipitate was filtered, washed with ethanol, and dried. Recrystallization from ethanol gave the product as a white solid (9.76 g).

Step (b): Preparation of: 6,7-Dichloro-3-(4-pyridyl)-2-quinoxalinol

A solution of ethyl 4-pyridylglyoxylate oxime (3.35 g) and 4,5-dichlorophenylenediamine (3.05 g) in 35% sulfuric acid (75 mL) was stirred at 75°C for 16 hours. The solid, which formed on heating, was removed by filtration and triturated in water. The remaining solid was filtered, dissolved in hot ethanol, and made basic with concentrated NH₄OH. This mixture was cooled and diluted with water. The precipitate was collected by filtration and recrystallized from ethanol to give the product as a gray solid (6.20 g).

Step (c): Preparation of: 2,6,7-Trichloro-3-pyridin-4-yl-quinoxaline

A slurry of 6,7-dichloro-3-(3-pyridyl)-2-quinoxalinol (3.5 g) in phosphorous oxychloride (35 mL) was refluxed for 6 hours. The resulting mixture was cooled, poured over ice, stirred for 15 minutes, and made basic with concentrated NH₄OH. The precipitate was removed by filtration and recrystallization from ethanol gave the product as white crystals (0.62 g).

Step (d): Preparation of: N-(6,7-Dichloro-3-pyridin-4-yl-quinoxalin-2-yl)-N',N'-dimethyl-cyclohexane-1,4-diamine

A solution of 2,6,7-trichloro-4-pyridin-3-yl-quinoxaline (0.31 g) and N,N-dimethyl-cyclohexane-1,4-diamine (0.28 g) in toluene (30 mL) was refluxed under nitrogen atmosphere for 24 hours. Potassium carbonate (0.14 g) was added

-105-

to the reaction and the reaction mixture refluxed an additional 24 hours. The reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give a yellow solid. This solid was recrystallized from methanol to give the product as yellow crystals (0.078 g); mp 183-185°C.

EXAMPLE 50

N-(6,7-Dimethoxy-3-pyridin-2-yl-quinoxalin-2-yl)-N',N'-dimethyl-cyclohexane-1,4-diamine

Step (a): Preparation of: 6,7-Dimethoxy-3-(2-pyridyl)-2-quinoxalinol

A solution of ethyl 2-pyridylglyoxylate oxime (3.35 g) and 4,5-dimethoxyphenylenediamine (3.05 g) in 35% sulfuric acid (75 mL) was stirred at 75°C for 17 hours. The solid, which formed on heating, was removed by filtration and dissolved in water. The solution was adjusted to pH 8 with concentrated NH₄OH. The precipitate removed by filtration and washed with water. This solid was recrystallized from ethanol to give the product as a light brown solid (3.64 g).

Step (b): Preparation of: 2-Chloro-6,7-dimethoxy-3-pyridin-2-yl-quinoxaline

A slurry of 6,7-dimethoxy-3-(2-pyridyl)-2-quinoxalinol (2.0 g) in phosphorous oxychloride (20 mL) was refluxed for 18 hours. The resulting mixture was cooled, poured over ice, stirred for 5 minutes, and made basic with concentrated NH₄OH. The precipitate was removed by filtration and purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give the product as white solid (1.6 g); mp 146-147°C.

Step (c): Preparation of: N-(6,7-Dimethoxy-3-pyridin-2-yl-quinoxalin-2-yl)-N',N'-dimethyl-cyclohexane-1,4-diamine

A solution of 2-chloro-6,7-dimethoxy-3-pyridin-2-yl-quinoxaline (0.91 g) and N,N-dimethyl-cyclohexane-1,4-diamine (0.86 g) in toluene (30 mL) was refluxed under nitrogen atmosphere for 16 hours. The reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give a yellow solid.

-106-

This solid was recrystallized in ethyl acetate/hexane to give the product as yellow crystals (0.92 g); mp 168-171°C.

EXAMPLE 51

5 N,N-Dimethyl-N'-(3-pyridin-2-yl-7,8-dihydro-6H-cyclopenta[g]quinoxalin-2-yl)-
cyclohexane-1,4-diamine

Step (a): Preparation of: 5,6-Diaminoindane

10 A solution of 5-amino-6-nitroindane (2.0 g) in THF (200 mL) was hydrogenated at room temperature over a Raney nickel catalyst (1.0 g) for 4 hours. The catalyst was removed by filtration and the filtrate evaporated. Recrystallization of the residue from methanol and water gave the product as pale purple crystals (1.53 g).

Step (b): Preparation of: 3-Pyridin-2-yl-7,8-dihydro-6H-
cyclopenta[g]quinoxalinol

15 A solution of ethyl 2-pyridylglyoxylate oxime (1.86 g) and 5,6-diaminoindane (1.42 g) in 35% sulfuric acid (33 mL) was stirred at 75°C for 16 hours. The solid, which formed on heating, was removed by filtration and dissolved in water. The solution was adjusted to pH 8 with concentrated NH₄OH, the precipitate removed by filtration and washed with water. This solid was recrystallized from ethanol to give the product as a pale yellow solid (1.29 g).

20 Step (c): Preparation of: 2-Chloro-3-pyridin-2-yl-7,8-dihydro-6H-
cyclopenta[g]quinoxaline

25 A slurry of 3-pyridin-2-yl-7,8-dihydro-6H-cyclopenta[g]quinoxalinol (1.0 g) in phosphorous oxychloride (20 mL) was refluxed for 16 hours. The resulting mixture was cooled, poured over ice, stirred for 5 minutes, and made basic with concentrated NH₄OH. The precipitate was removed by filtration and purified by flash chromatography (silica gel, dichloromethane) to the product as light brown powder (1.6 g).

-107-

Step (d): Preparation of: N,N-Dimethyl-N'-(3-pyridin-2-yl-7,8-dihydro-6H-cyclopenta[g]quinoxalin-2-yl)-cyclohexane-1,4-diamine

A solution of 2-chloro-3-pyridin-2-yl-7,8-dihydro-6H-cyclopenta[g]quinoxaline (0.5 g) and N,N-dimethyl-cyclohexane-1,4-diamine (0.51 g) in toluene (30 mL) was refluxed under nitrogen atmosphere for 16 hours. The reaction was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:19 methanol/dichloromethane) to give a yellow solid. Recrystallization from methanol and water gave the product as yellow crystals (0.3 g); mp 158-161°C.

EXAMPLE 52

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-ethane-1,2-diamine

A solution of 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (0.50 g) and N,N-dimethyl-ethane-1,2-diamine (0.28 g) in toluene (20 mL) was refluxed under nitrogen atmosphere for 16 hours. After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give the product as a yellow solid (0.26 g); mp 95-97°C.

EXAMPLE 53

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-diamine

A solution of 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (0.50 g) and 3-N,N-dimethylamino-propylamine (0.32 g) in toluene (20 mL) was refluxed under nitrogen for 16 hours. After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give the product as a yellow solid (0.43 g); mp 59-61°C.

-108-

EXAMPLE 54

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-butane-1,4-diamine

5 A solution of 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (0.50 g) and 4-N,N-dimethylamino-butylamine (0.36 g) in toluene (20 mL) was refluxed under nitrogen for 16 hours. After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give a yellow solid. Recrystallization from methanol and water gave the product as yellow crystals
10 (0.34 g); mp 81-83°C.

EXAMPLE 55

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-pentane-1,5-diamine

Step (a): Preparation of: (5-Amino-pentyl)-carbamic acid *tert*-butyl ester
15 To a solution of putrescine (5.2 g) in dry THF (150 mL) at 0°C under nitrogen atmosphere was added a chilled solution of di-*tert*-butyl dicarbonate (3.7 g) in THF (100 mL). When the addition was complete, the resulting mixture was warmed to room temperature and stirred 1 hour. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined extracts were
20 washed with water and brine. The organic phase was dried over MgSO₄ and concentrated under vacuum to give the product as a waxy white solid (2.8 g). (Blagbroug I. S., Moya E., Walford S. P., *Tetrahedron. Letters*, 1996;37:551.)

Step (b): Preparation of: [N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-5-amino-pentyl]-carbamic acid *tert*-butyl ester

25 A solution of 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (2.2 g) and (5-amino-pentyl)-carbamic acid *tert*-butyl ester (2.8 g) in toluene (50 mL) was refluxed under nitrogen atmosphere for 16 hours. After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give a yellow

-109-

solid. Recrystallization from ethanol and water gave the product as a yellow solid (2.1 g).

Step (c): Preparation of: N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-pentane-1,5-diamine

5 [N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-5-amino-pentyl]-carbamic acid *tert*-butyl ester (1.0 g) was placed in a solution of hydrochloride gas in methanol and stirred 2 hours. The reaction mixture was treated with 2N KOH solution, stirred, and diluted with water. This mixture was filtered to give the product as a yellow solid (0.98 g).

10 Step (d): Preparation of: N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-pentane-1,5-diamine

A solution of N-(6,7-trichloro-3-pyridin-2-yl-quinoxalin-2-yl)-pentane-1,5-diamine (0.98 g) and formic acid (0.83 g) in formalin (7.5 mL) was heated on a steam bath for 16 hours. This mixture was diluted with methanol (30 mL) and
15 treated with 2N HCl solution. After stirring 20 minutes, 2N KOH solution was added. The precipitate was collected by filtration and purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give a yellow solid. Recrystallization from methanol and water gave the product as a yellow powder (0.083 g); mp 100-102°C.

20 EXAMPLE 56

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-hexane-1,6-diamine

A solution of 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (0.50 g) and 6-dimethylamino-hexylamine (0.46 g) in toluene (25 mL) was refluxed under
25 nitrogen atmosphere for 16 hours. After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give a yellow solid. Recrystallization from methanol and water gave the product as a fluffy yellow powder (0.41 g); mp 88-90°C.

-110-

EXAMPLE 57

[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylsulfanyl)-propyl]-dimethylamine

To a solution 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (0.50 g) and dimethylaminopropanethiol hydrochloride (0.25 g) in toluene (20 mL) was added pyridine (0.25 mL). The resulting mixture was refluxed under nitrogen atmosphere for 16 hours. After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give a yellow solid. Recrystallization from methanol and water gave the product as a fluffy yellow powder (0.25 g); mp 82-84°C.

EXAMPLE 58

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(3-morpholin-4-yl-propyl)-amine

A solution of 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (0.50 g) and N-(3-aminopropyl)-morpholine (0.46 g) in toluene (25 mL) was refluxed under nitrogen for 16 hours. After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give a yellow solid. Recrystallization from methanol and water gave the product as yellow crystals (0.56 g); mp 119-121°C.

EXAMPLE 59

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(3-methoxypropyl)-amine

A solution of 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (0.50 g) and 3-methoxypropylamine (0.28 g) in toluene (20 mL) was refluxed under nitrogen for 16 hours. After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was recrystallized from methanol and water to give the product as a yellow solid (0.45 g); mp 99.5-100.5°C.

EXAMPLE 60

N'-1-[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylamino)-propyl]-N'-1-methylpropane-1,3-diamine

-111-

Step (a): Preparation of: {3-[(3-Amino-propyl)-methyl-amino]-propyl}-carbamic acid *tert*-butyl ester

To a solution of 3,3-diamino-N-methyldipropylamine (4.4 g) in dry THF (70 mL) at 0°C under nitrogen was added a chilled solution of di-*tert*-butyl dicarbonate (2.2 g) in THF (75 mL). When the addition was complete, the resulting mixture was slowly warmed to room temperature and stirred 1 hour. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined extracts were washed with water and brine. The organic phase was dried over sodium sulfate then concentrated under vacuum to give the product as waxy white solid (2.3 g).

Step (b): Preparation of: N'-1-[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylamino)-propyl]-N'-1-methyl-propane-1,3-diamine

A solution of 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (0.90 g) and {3-[(3-amino-propyl)-methyl-amino]-propyl}-carbamic acid *tert*-butyl ester (0.14 g) in toluene (30 mL) was refluxed under nitrogen atmosphere for 16 hours. After refluxing, the reaction mixture was cooled and filtered, then treated with HCl gas. The precipitate was collected by filtration, dissolved in chloroform, and washed with 10% aqueous potassium carbonate solution. The organic phase was concentrated under vacuum, and the residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give the product as a brown oil (0.62 g).

EXAMPLE 61

2-{[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylamino)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol

A solution of 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (0.50 g) and 3-[bis(2-hydroxy-ethyl)amino]-propylamine (0.51 g) in toluene (25 mL) was refluxed under nitrogen atmosphere for 16 hours. After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/ dichloromethane) to give a yellow solid. Recrystallization from methanol and water gave the product as a yellow plate like crystals (0.55 g); mp 88-90°C.

-112-

EXAMPLE 62

{4-[4-(2-Chloro-phenyl)-piperidin-1-yl]-butyl-(6,7-Dichloro-3-pyridin-2-yl-
quinoxalin-2-yl)} amine

5 A solution of 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (0.31 g) and 4-[(2-chloro-phenyl)-1-piperazine]butylamine (0.53 g) in toluene (25 mL) was refluxed under nitrogen atmosphere for 16 hours. After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/ dichloromethane) to give a brown solid. Recrystallization from methanol and water gave the product as a yellow
10 crystals (0.29 g); mp 116-118°C.

EXAMPLE 63


(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(1-phenyl-4-piperdin-1-yl-butyl)-
amine

15 To a solution 2,6,7-trichloro-3-pyridin-2-yl-quinoxaline (0.31 g) and alpha-phenyl-1-piperidine-butylamine dihydrochloride (0.31 g) in toluene (25 mL) was added triethylamine (0.50 mL). The resulting mixture was refluxed under nitrogen atmosphere for 36 hours. After refluxing, the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 1:9 methanol/dichloromethane) to give a yellow solid.
20 Recrystallization from methanol and water gave the product as a fluffy yellow powder (0.32 g); mp 125-127°C.

EXAMPLE 64

(6,7-Dichloro-3-(1-ethyl-5-phenyl-imidazol-2-yl)-quinoxalin-2-yl)]-(4-pyrrolidin-1-yl-butyl)-amine

25




-113-

A solution of 1-ethyl-5-phenylimidazole (220 mg, 1.28 mmol) in anhydrous THF (10 mL) was cooled in an ice bath and treated with n-butyllithium (2.5 M, 0.56 mL, 1.41 mmol), and stirred for 30 minutes. The resulting brown solution was treated with anhydrous ZnCl₂ (354 mg, 2.6 mmol) in THF (10 mL) and allowed to warm to room temperature. After 30 minutes, the resulting organozinc reagent was treated with aminoquinoxaline bromide and catalyst (PdCl₂(PPh₃)₂ 42 mg, 0.06 mmol and n-butyllithium 0.048 mL, 0.12 mmol in anhydrous THF (3 mL). The mixture was heated to reflux for 18 hours, followed by removal of the solvent *in vacuo*. The residue was chromatographed on silica gel eluting with 10% CH₃OH and 3% Et₃N in ethyl acetate to give the free base as a viscous oil (67 mg, 20%). The bis-HCl salt was prepared by treating the free base with methanolic HCl; ¹H NMR (free-base, CDCl₃) δ 1.38 (t, 3H), 1.80 (m, 8H), 2.55 (m, 6H), 3.65 (m, 2H), 4.65 (m, 2H), 7.18 (m, 1H), 7.46 (m, 5H), 7.73 (s, 1H), 7.81 (s, 2H), 10.16 (broad s, 1H); Anal. Calcd for C₂₇H₃₀N₆Cl₂·2HCl: C, 55.7; H, 5.53; N, 14.43. Found: C, 56.15; H, 5.73; N, 14.08.

EXAMPLE 65

[6,7-Dichloro-3-(1-phenyl-imidazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine




The title compound was prepared according to the experimental procedure for Example 64; ¹H NMR (free-base, CDCl₃) δ 1.80 (m, 8H), 2.60 (m, 6H), 3.64 (m, 2H), 7.02 (m, 1H), 7.30 (m, 4H), 7.45 (m, 3H), 7.68 (m, 1H), 9.66 (broad s, 1H); Anal. Calcd for C₂₅H₂₆N₆Cl₂·2HCl·0.6H₂O·0.3CH₃OH: C, 52.86; H, 5.33; N, 14.62. Found: C, 53.02; H, 5.27; N, 14.24.

-114-

EXAMPLE 66


[6,7-Dichloro-3-[1-ethyl-5-(5-methyl-thiophene-2-yl)-imidazol-5-yl]-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine



- 5 The title compound was prepared according to the experimental procedure for Example 64; ^1H NMR (free-base, CDCl_3) δ 1.50 (t, 3H), 1.76 (m, 8H), 2.50 (s, 9H), 3.63 (q, 2H), 4.72 (q, 2H), 6.81 (d, 1H), 6.99 (d, 1H), 7.22 (s, 1H), 7.73 (s, 1H), 7.82 (s, 1H), 10.04 (broad t, 1H); Anal. Calcd for $\text{C}_{26}\text{H}_{30}\text{N}_6\text{S}\text{Cl}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O} \cdot 0.8\text{CH}_3\text{OH}$: C, 52.80; H, 5.98; N, 13.78. Found: C, 52.47; H, 5.51; N, 13.51.
- 10

EXAMPLE 67


[6,7-Dichloro-3-(1-phenyl-pyrazol-5-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine



- 15 The title compound was prepared according to the experimental procedure for Example 16; ^1H NMR (free-base, CDCl_3) δ 1.53 (m, 4H), 1.75 (m, 4H), 2.44 (m, 6H), 3.41 (m, 2H), 5.29 (m, 1H), 6.81 (d, $j = 1.8$ Hz, 1H), 7.29 (m, 5H), 7.77 (s, 1H), 7.78 (s, 1H), 7.86 (d, $j = 1.8$ Hz, 1H); Anal. Calcd for $\text{C}_{25}\text{H}_{26}\text{N}_6\text{Cl}_2 \cdot 2\text{HCl} \cdot \text{H}_2\text{O}$: C, 52.46; H, 5.28; N, 14.68. Found: C, 53.18; H, 5.23; N, 14.39.
- 20


-115-
CLAIMS

1. A compound of Formula I



I

wherein A is selected from the group consisting of:



wherein R³, R^{3a}, and R^{3b} are each independently the

same or different and are hydrogen,

alkyl,

aryl-SO₂-,

aryl,

heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

alkyl,

aryl,

aralkyl,

acetyl, or

-(CH₂)_m-N-R⁵ wherein
|
R⁶

R⁵ and R⁶ are each the same or different and are

hydrogen, alkyl, cycloalkyl, acetyl,

-(CH₂)_m-OH, or

R⁵ and R⁶ are taken together to form a 5- to 7-membered ring optionally containing an

-116-

oxygen atom or N-R⁴ wherein R⁴ is as
defined above and m is an integer of 2 to 5,

-(CH₂)_n-N-R⁷ wherein n is zero or an integer of 1 and R⁷ and R⁸

5



are each independently the same or different and are hydrogen,

alkyl,

aryl,

aralkyl,

10

acetyl, or

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are as defined



15

above or R⁷ and R⁸ taken together to form a
5- to 7-membered ring optionally containing
an oxygen atom or N-R⁴ wherein R⁴ and m
are as defined above,

-(CH₂)_n-CON-R⁷ wherein R⁷, R⁸, and n are as defined above,

20



-(CH₂)_n-SO₂N-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂OR⁴ wherein R⁴ and n are as defined above,

25

-(CH₂)_n-CO₂R⁴ wherein R⁴ and n are as defined above,

-CH₂OR⁴ wherein R⁴ is as defined above,

halogen,

CF₃,









CBr₃,

30

CCl₃, or

NO₂,









-117-

wherein R^3 and R^{3a} are as defined above,wherein R^3 and R^{3a} are as defined above,wherein R^3 and R^{3a} are as defined above,wherein R^3 and R^{3a} are as defined above,wherein R^3 and R^{3a} are as defined above,wherein R^3 and R^{3a} are as defined above,wherein R^3 and R^{3a} are as defined above, andwherein o is an integer of 1 or 2, and R^9 is hydrogen or

alkyl;


5

-118-




and R³ and R^{3a} are as defined above,


-119-




above,




above,




above,



above,




above,




above,


-120-

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined

above,

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as


defined above,

10

-121-




above,





above,

5




above,




above,

10




above,

-122-







above,





above,


5





10






-123-





above,



5





10



halogen, or
alkoxy, with the proviso

-124-

that when A is  wherein R³ is hydrogen,

methyl, or chloro, R¹ is not 


wherein R³ is hydrogen; and

R² is CF₃,

5

CCl₃,

CBr₃, or




10

wherein R¹⁰ is hydrogen,

alkyl, or

aralkyl, and

R¹¹ is 

wherein n, R⁵, and R⁶ are as defined above,


15

-(CH₂)_m-N-R⁵ wherein R⁵, R⁶, and m are as defined



above,

20

 wherein R¹² and R^{12a} are each

independently the same or different and are hydrogen,

25


alkyl, or aryl, or taken together can form a 5- to

7-membered ring, and


R¹³ is hydrogen or alkyl, and

-125-



m is as defined above,




above,




above,






above,



defined above,



above,




-126-

R^{10} and R^{11} when taken together can form a 5- to 7-membered ring optionally containing an oxygen atom or $N-R^4$ wherein R^4 is as defined above;

or a pharmaceutically acceptable salt thereof.

- 5 2. The compound of Claim 1 wherein A is selected from the group consisting of:



wherein R^3 , R^{3a} , and R^{3b} are each independently the

same or different and are hydrogen,

alkyl,

10

aryl,

heteroaryl,

$-OR^4$ wherein R^4 is hydrogen,

alkyl,

aryl,

15

aralkyl,

acetyl, or

$-(CH_2)_m-N-R^5$ wherein R^5 and R^6 are each the same or



20

different and are hydrogen,

alkyl, cycloalkyl, acetyl, or

R^5 and R^6 are taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or $N-R^4$ wherein R^4 is as defined above and m is an integer of 2 to 5,

25

$-(CH_2)_n-N-R^7$ wherein n is zero or an integer of 1 and R^7 and R^8



-127-

are each independently the same or different and are hydrogen,

alkyl,

aryl,

aralkyl,

5 acetyl, or

$-(CH_2)_m-N-R^5$ wherein R^5 and R^6 are as defined

|
 R^6

above or R^7 and R^8 taken together to form a 5- to

10 7-membered ring optionally containing an oxygen atom or

$N-R^4$ wherein R^4 and m are as defined above,

$-(CH_2)_n-CON-R^7$ wherein R^7 , R^8 , and n are as defined above,

|
 R^8

15 $-(CH_2)_n-SO_2N-R^7$ wherein R^7 , R^8 , and n are as defined above,

|
 R^8

$-(CH_2)_n-SO_2OR^4$ wherein R^4 and n are as defined above,

$-(CH_2)_n-CO_2R^4$ wherein R^4 and n are as defined above,

20 $-CH_2OR^4$ wherein R^4 is as defined above,


halogen,

CF_3 ,

CBr_3 ,





CCl_3 , or

25 NO_2 ,







wherein R^3 and R^{3a} are as defined above,


-128-




5




-129-

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined

above,

wherein R^3 , R^{3a} , and R^{3b} are as defined

above,


wherein R^3 , R^{3a} , and R^{3b} are as

defined above,


5

10

-130-




above,





above,

5




above,




above,

10





above,

-131-



above,



5 halogen, or
alkoxy; and

R^2 is CF_3 ,

CCl_3 ,


CBr_3 , or

10 $-N-R^{10}$ wherein R^{10} is hydrogen and
|
 R^{11}

R^{11} is $-(CH_2)_m-N-R^5$ wherein m , R^5 , and R^6 are as
defined

15


|
 R^6



and R^6 are as defined above.

3. The compound of Claim 2 wherein A is

-132-



wherein R^3 , R^{3a} , and R^{3b} are each independently the

same or different and are hydrogen,

alkyl,

aryl,

5

heteroaryl,

$-OR^4$ wherein R^4 is hydrogen,

alkyl,

aryl,

aralkyl,

10

acetyl, or

$-(CH_2)_m-N-R^5$ wherein



R^5 and R^6 are each the same or different and are
hydrogen,

15

alkyl, cycloalkyl, acetyl, or

R^5 and R^6 are taken together to form a 5- to
7-membered ring optionally containing an
oxygen atom or $N-R^4$ wherein R^4 is as
defined above and m is an integer of 2 to 5,

20

$-(CH_2)_n-N-R^7$ wherein n is zero or an integer of 1 and R^7 and R^8



are each independently the same or different and are
hydrogen,

25

alkyl,

aryl,

aralkyl,

acetyl, or

-133-

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are as defined



above or R⁷ and R⁸ taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or N-R⁴ wherein R⁴ and m are as defined above,

-(CH₂)_n-CON-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂N-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂OR⁴ wherein R⁴ and n are as defined above,

-(CH₂)_n-CO₂R⁴ wherein R⁴ and n are as defined above,

-CH₂OR⁴ wherein R⁴ is as defined above,


halogen,

CF₃,


CBr₃,

CCl₃, or

NO₂;







wherein R³, R^{3a}, and R^{3b} are as defined above,






wherein R³, R^{3a}, and R^{3b} are as defined above,


-134-



5



10




-135-

R^2 is CF_3 ,
 CCl_3 ,
 CBr_3 , or
 $-N-R^{10}$ wherein R^{10} is hydrogen and
 $|$
 R^{11}


R^{11} is $-(CH_2)_m-N-R^5$ wherein m , R^5 , and R^6 are as
 $|$
 R^6

defined above, or



are as defined above.

4. The compound of Claim 3 wherein



the same or different and are hydrogen,

alkyl,

aryl,

heteroaryl,

$-OR^4$ wherein R^4 is hydrogen,

alkyl,

aryl,

heteroaryl,

aralkyl,

acetyl, or

$-(CH_2)_m-N-R^5$ wherein
 $|$
 R^6

-136-

R^5 and R^6 are each the same or different and are hydrogen,

alkyl, cycloalkyl, acetyl, or

R^5 and R^6 are taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or $N-R^4$ wherein R^4 is as defined above and m is an integer of 2 to 5,

$-(CH_2)_n-N-R^7$ wherein n is zero or an integer of 1 and R^7 and R^8

$$\begin{array}{c} | \\ R^8 \end{array}$$

are each independently the same or different and are hydrogen,

alkyl,

aryl,

aralkyl,

acetyl, or

$-(CH_2)_m-N-R^5$ wherein R^5 and R^6 are as defined

$$\begin{array}{c} | \\ R^6 \end{array}$$

above or R^7 and R^8 taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or $N-R^4$ wherein R^4 and m are as defined above,

$-(CH_2)_n-CON-R^7$ wherein R^7 , R^8 , and n are as defined above,

$$\begin{array}{c} | \\ R^8 \end{array}$$

$-(CH_2)_n-SO_2N-R^7$ wherein R^7 , R^8 , and n are as defined above,

$$\begin{array}{c} | \\ R^8 \end{array}$$

$-(CH_2)_n-SO_2OR^4$ wherein R^4 and n are as defined above,

$-(CH_2)_n-CO_2R^4$ wherein R^4 and n are as defined above,





$-CH_2OR^4$ wherein R^4 is as defined above,

-137-




halogen,

CF₃,CBr₃,CCl₃, orNO₂;

5




10



-138-


above, or

wherein R^3 and R^{3a} are as defined above; and R^2 is CF_3 , CCl_3 ,

5

 CBr_3 , or $-N-R^{10}$ wherein R^{10} is hydrogen and

10


 R^{11} is $-(CH_2)_m-N-R^5$ wherein m , R^5 , and R^6 are as

defined above, or

wherein n , R^5 , and R^6 are as defined above.

5. The compound of Claim 4 wherein

15



A is

wherein R^3 , R^{3a} , and R^{3b} are each independently

the same or different and are hydrogen,

alkyl,

aryl,

heteroaryl,

20

 $-OR^4$ wherein R^4 is hydrogen,


alkyl,

aryl,

aralkyl,


acetyl, or

-139-



or different and are hydrogen,

alkyl, cycloalkyl, acetyl, or

 R^5 and R^6 are taken together to form a 5- to 7-membered ring optionally containing an
oxygen atom or $\text{N}-\text{R}^4$ wherein R^4 is asdefined above and m is an integer of 2 to 5,



are each independently the same or different and are hydrogen,

alkyl,


aryl,

aralkyl,

acetyl, or

above or R^7 and R^8 taken together to form a 5- to 7-membered ring optionally containingan oxygen atom or $\text{N}-\text{R}^4$ wherein R^4 and m are as defined above,

above,



above,

-140-

-(CH₂)_n-SO₂OR⁴ wherein R⁴ and n are as defined above,

-(CH₂)_n-CO₂R⁴ wherein R⁴ and n are as defined above,

-CH₂OR⁴ wherein R⁴ is as defined above,







halogen,

CF₃,

CBr₃,

CCl₃, or

NO₂;




-141-

R² is -N-R¹⁰ wherein R¹⁰ is hydrogen and



R¹¹ is -(CH₂)_m-N-R⁵ wherein m, R⁵, and R⁶ are as defined

5



are as defined above.

6. A compound which is selected from the group consisting of:

10

N-(1-Azabicyclo[2.2.2]octan-3-yl)-3-(2-pyridinyl)-2-
quinoxalinamine;

N-[3-(1H-Imidazol-1-yl)propyl]-3-(2-pyridinyl)-2-
quinoxalinamine;

15

N-[2-(1-Methyl-2-pyrrolidinyl)ethyl]-3-(2-pyridinyl)-2-
quinoxalinamine;

1-[3-[[3-Pyridinyl)-2-quinoxalinamine]amino]propyl]-2-
pyrrolidinone;

N-[4-(4-Morpholinyl)phenyl]-3-(2-pyridinyl)-2-quinoxalinamine;

N-(4-Piperidinylmethyl)-3-(2-pyridinyl)-2-quinoxalinamine;

20

N-[4-(Dimethylamino)phenyl]-3-(2-pyridinyl)-2-quinoxalinamine;

N-Methyl-N-[4-[[3-(2-pyridinyl)-2-quinoxalinyl]amino]phenyl]-
acetamide;

N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N',N'-dimethyl-
cyclohexane-1,4-diamine;

25

N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-cyclohexane-1,4-
diamine;


2-[1,4']Bipiperidinyl-1'-yl-6,7-dichloro-3-pyridin-2-yl-quinoxaline;

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(4-
diethylaminomethyl-phenyl)-amine;

-142-




N'-(6,7-Dichloro-3-furan-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
propane-1,3-diamine;

N'-(6,7-Dichloro-3-thiophen-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
propane-1,3-diamine;





5

N'-(6,7-Difluoro-3-thiophen-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
butane-1,4-diamine;




10

-143-




N'-[6,7-Dichloro-3-(1H-indol-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;



5

N'-(3-Benzo[b]thiophen-2-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;







10

N,N-Diethyl-N'-(3-thiophen-2-yl-7-trifluoromethyl-quinoxalin-2-yl)-butane-1,4-diamine;

N'-[6,7-Dichloro-3-(5-methyl-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;

-144-



5 N'-(6,7-Dichloro-3-thiazol-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-diamine;

N'-(3-[2,2']Bithiophenyl-5-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;


10 N'-[6,7-Dichloro-3-(5-chloro-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;

N'-[6,7-Dichloro-3-(5-methoxy-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;

N'-[6,7-Dichloro-3-(5-propyl-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;


-145-

N'-(3-Benzofuran-2-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;



N'-[6,7-Dichloro-3-dibenzothiophen-4-yl-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;



5





[6,7-Dichloro-3-(5-phenyl-oxazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

[6,7-Dichloro-3-(5-thiophen-2-yl-oxazol)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

10



-146-



N-(6,7-Dichloro-3-pyridin-3-yl-quinoxalin-2-yl)-N',N'-dimethyl-
cyclohexane-1,4-diamine;

5 N-(6,7-Dichloro-3-pyridin-4-yl-quinoxalin-2-yl)-N',N'-dimethyl-
cyclohexane-1,4-diamine;

N-(6,7-Dimethoxy-3-pyridin-2-yl-quinoxalin-2-yl)-N',N'-dimethyl-
cyclohexane-1,4-diamine;

10 N,N-Dimethyl-N'-(3-pyridin-2-yl-7,8-dihydro-6H-
cyclopenta[g]quinoxalin-2-yl)-cyclohexane-1,4-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
ethane-1,2-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
propane-1,3-diamine;

15 N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
butane-1,4-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
pentane-1,5-diamine;

20 N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-pentane-1,5-
diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
hexane-1,6-diamine;

-147-

[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylsulfanyl)-propyl]-
dimethylamine;

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(3-morpholin-4-yl-
propyl)-amine;

5 (6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(3-methoxypropyl)-
amine;

N'-1-[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylamino)-
propyl]-N'-1-methyl-propane-1,3-diamine;

10 2-{[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylamino)-propyl]-
(2-hydroxy-ethyl)-amino}-ethanol;

{4-[4-(2-Chloro-phenyl)-piperidin-1-yl]-butyl-(6,7-dichloro-3-
pyridin-2-yl-quinoxalin-2-yl)} amine;

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(1-phenyl-4-
piperidin-1-yl-butyl)-amine;

15 [6,7-Dichloro-3-(1-ethyl-5-phenyl-imidazol-2-yl)-quinoxalin-2-yl]-
(4-pyrrolidin-1-yl-butyl)-amine;


[6,7-Dichloro-3-(1-phenyl-imidazol-2-yl)-quinoxalin-2-yl]-(4-
pyrrolidin-1-yl-butyl)-amine;

20 [6,7-Dichloro-3-[1-ethyl-5-(5-methyl-thiophene-2-yl)-imidazol-5-
yl]-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine; and

[6,7-Dichloro-3-(1-phenyl-pyrazolo-5-yl)-quinoxalin-2-yl]-(4-
pyrrolidin-1-yl-butyl)-amine;

or a pharmaceutically acceptable salt thereof.


25 7. A method of treating a chemokine-mediated disease state, wherein the
chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor in a
mammal, which comprises administering to said mammal an effective
amount of a compound of Formula II



II

wherein A is selected from the group consisting of:

-148-



wherein R^3 , R^{3a} , and R^{3b} are each independently the

same or different and are hydrogen,

alkyl,

aryl-SO₂-,

5

aryl,

heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

alkyl,

aryl,

10

aralkyl,

acetyl, or

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are each the same



15

or different and are hydrogen,

alkyl, cycloalkyl, acetyl, -(CH₂)_m-OH, or

R⁵ and R⁶ are taken together to form a 5- to

7-membered ring optionally containing an

oxygen atom or N-R⁴ wherein R⁴ is as

20

defined above and m is an integer of 2 to 5,

-(CH₂)_n-N-R⁷ wherein n is zero or an integer of 1 and R⁷ and R⁸



25

are each independently the same or different and are
hydrogen,

alkyl,

aryl,

aralkyl,

acetyl, or

-149-

$$-(\text{CH}_2)_m-\text{N}-\text{R}^5 \text{ wherein } \text{R}^5 \text{ and } \text{R}^6 \text{ are as defined}$$


above or R^7 and R^8 taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or $\text{N}-\text{R}^4$ wherein R^4 and m are as defined above,

$$-(\text{CH}_2)_n-\text{CON}-\text{R}^7 \text{ wherein } \text{R}^7, \text{R}^8, \text{ and } n \text{ are as defined above,}$$





$$-(\text{CH}_2)_n-\text{SO}_2\text{N}-\text{R}^7 \text{ wherein } \text{R}^7, \text{R}^8, \text{ and } n \text{ are as defined above,}$$


$$-(\text{CH}_2)_n-\text{SO}_2\text{OR}^4 \text{ wherein } \text{R}^4 \text{ and } n \text{ are as defined above,}$$





$$-(\text{CH}_2)_n-\text{CO}_2\text{R}^4 \text{ wherein } \text{R}^4 \text{ and } n \text{ are as defined above,}$$

$$-\text{CH}_2\text{OR}^4 \text{ wherein } \text{R}^4 \text{ is as defined above}$$


halogen,

 CF_3 , CBr_3 , CCl_3 , or NO_2 ,wherein R^3 and R^{3a} are as defined above,wherein R^3 and R^{3a} are as defined above,wherein R^3 and R^{3a} are as defined above,




-150-







5




hydrogen or alkyl;





-151-



5




and R^3 and R^{3a} are as defined above,




10

-152-




above,




above,


5



above,




above,




10

above,




above,


-153-

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as

defined above,

wherein R^3 , R^{3a} , and R^{3b} are as defined

above,


wherein R^3 , R^{3a} , and R^{3b} are as defined

above,



5

10


-154-

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

wherein R^3 , R^{3a} , and R^{3b} are as defined

above,

wherein R^3 , R^{3a} , and R^{3b} are as defined




above,

wherein R^3 and R^{3a} are as defined above,





5

10


-155-




5





10



-156-


wherein R³, R^{3a}, and R^{3b} are as defined

above,


wherein R³ and R^{3a} are as defined above,wherein R³, R^{3a}, and R^{3b} are as

5


defined above,

wherein R³, R^{3a}, and R^{3b} are as

defined above,

wherein R³, R^{3a}, and R^{3b} are as

defined above,



10

alkyl,

halogen,

alkoxy,

OR⁴ wherein R⁴ is as defined above, or

15

-(CH₂)_n- N-R⁷ wherein R⁷, R⁸, and n are as defined above; andR^{2a} is CF₃,


-157-

CCl₃,CBr₃, or-N-R¹⁰ wherein R¹⁰ is hydrogen,
$$\begin{array}{c} | \\ \text{R}^{11} \end{array}$$

5

alkyl, or

aralkyl, and

R¹¹ is  wherein n, R⁵,

and R⁶ are as defined above,

10

-(CH₂)_m-N-R⁵ wherein R⁵, R⁶, and m are as defined
$$\begin{array}{c} | \\ \text{R}^6 \end{array}$$

above,

15

$$\begin{array}{c} \text{N-R}^{13} \\ || \end{array}$$
-(CH₂)_m-N-C-N-R¹² wherein R¹² and R^{12a} are each
$$\begin{array}{cc} | & | \\ \text{R}^{12} & \text{R}^{12a} \end{array}$$

independently the same or different and are hydrogen,

20

alkyl, or aryl, or taken together can form a 5- to

7-membered ring, and

R¹³ is hydrogen or alkyl, and


m is as defined above,

25

$$\begin{array}{c} \text{N-R}^{13} \\ || \end{array}$$
-(CH₂)_m-C-N-R¹² wherein m, R¹², R^{12a}, and R¹³ are as
$$\begin{array}{c} | \\ \text{R}^{12a} \end{array}$$



defined above,

30


—(CH₂)_m— wherein R⁹ and m are as defined

above,

-158-




above,





5


defined above,



above,



10




R^{10} and R^{11} when taken together can form a 5- to 7-membered ring optionally containing an oxygen atom or $N-R^4$ wherein R^4 is as defined above;

or a pharmaceutically acceptable salt thereof.

15

8. The compound of Claim 7 wherein A is selected from the group consisting of:

-159-



wherein R^3 , R^{3a} , and R^{3b} are each independently the

same or different and are hydrogen,

alkyl,

aryl,

5

heteroaryl,

$-OR^4$ wherein R^4 is hydrogen,

alkyl,

aryl,

aralkyl,

10

acetyl, or

$-(CH_2)_m-N-R^5$ wherein



R^5 and R^6 are each the same or different and are hydrogen,

15

alkyl, cycloalkyl, acetyl, or

R^5 and R^6 are taken together to form a 5- to

7-membered ring optionally containing an oxygen

atom or $N-R^4$ wherein R^4 is as defined above and

m is an integer of 2 to 5,

20

$-(CH_2)_n-N-R^7$ wherein n is zero or an integer of 1 and R^7 and R^8



are each independently the same or different and are hydrogen,

alkyl,

25

aryl,

aralkyl,

acetyl, or

-160-

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are as defined



above or R⁷ and R⁸ taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or N-R⁴ wherein R⁴ and m are as defined above,

-(CH₂)_n-CON-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂N-R⁷ wherein R⁷, R⁸, and n are as defined above,



-(CH₂)_n-SO₂OR⁴ wherein R⁴ and n are as defined above,

-(CH₂)_n-CO₂R⁴ wherein R⁴ and n are as defined above,

-CH₂OR⁴ wherein R⁴ is as defined above,


halogen,

CF₃,


CBr₃,

CCl₃, or

NO₂,







wherein R³ and R^{3a} are as defined above,







wherein R³ and R^{3a} are as defined above,


-161-




5




-162-

wherein R³, R^{3a}, and R^{3b} are as defined


above,

wherein R³, R^{3a}, and R^{3b} are as defined


above,

wherein R³, R^{3a}, and R^{3b} are as defined


above,

wherein R³, R^{3a}, and R^{3b} are as defined

above,

wherein R³, R^{3a}, and R^{3b} are as


defined above,

wherein R³, R^{3a}, and R^{3b} are as defined


above,

10

-163-



wherein R^3 , R^{3a} , and R^{3b} are as defined

above,


wherein R^3 , R^{3a} , and R^{3b} are as defined

above,

5


wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined

above,

wherein R^3 , R^{3a} , and R^{3b} are as defined


above,

10



wherein R^3 , R^{3a} , and R^{3b} are as defined

above,

-164-



above,



5 halogen, or
alkoxy; and


R^{2a} is CF_3 ,

CCl_3 ,

CBr_3 , or

10 $-N-R^{10}$ wherein R^{10} is hydrogen and
|
 R^{11}


15 R^{11} is $-(CH_2)_m-N-R^5$ wherein m , R^5 , and R^6 are as
|
 R^6



wherein n , R^5 , and R^6 are as defined above.

9. The compound of Claim 8 wherein A is

-165-



wherein R^3 , R^{3a} , and R^{3b} are each independently the

same or different and are hydrogen,

alkyl,

aryl,

heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

alkyl,

aryl,

aralkyl,

acetyl, or

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are each the same



or different and are hydrogen,

alkyl, cycloalkyl, acetyl, or

R⁵ and R⁶ are taken together to form a 5- to

7-membered ring optionally containing an

oxygen atom or N-R⁴ wherein R⁴ is as

defined above and m is an integer of 2 to 5,

-(CH₂)_n-N-R⁷ wherein n is zero or an integer of 1 and R⁷ and R⁸



are each independently the same or different and are
hydrogen,


alkyl,

aryl,





aralkyl,

acetyl, or

-166-



above or R^7 and R^8 taken together to form a
5- to 7-membered ring optionally containing
an oxygen atom or $\text{N}-\text{R}^4$ wherein R^4 and m
are as defined above,





halogen,

CF_3 ,





CBr_3 ,

CCl_3 , or




NO_2 ;




-167-



5



10




-168-

R^{2a} is CF₃,CCl₃,CBr₃, or-N-R¹⁰ wherein R¹⁰ is hydrogen and
$$\begin{array}{c} | \\ \text{R}^{11} \end{array}$$
R¹¹ is -(CH₂)_m-N-R⁵ wherein m, R⁵, and R⁶ are as
$$\begin{array}{c} | \\ \text{R}^6 \end{array}$$

defined above, or $\text{---}(\text{CH}_2)_n\text{---}\text{C}_6\text{H}_{10}\text{---}\text{N}\begin{array}{c} \text{---R}^5 \\ | \\ \text{R}^6 \end{array}$

wherein n, R⁵, and R⁶ are as defined above.

10. The compound of Claim 9 wherein

wherein R³, R^{3a}, and R^{3b} are each independently

the same or different and are hydrogen,

alkyl,

aryl,

heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

alkyl,

aryl,

aralkyl,

acetyl, or


-(CH₂)_m-N-R⁵ wherein
$$\begin{array}{c} | \\ \text{R}^6 \end{array}$$

R⁵ and R⁶ are each the same or different and are
hydrogen,

-169-

alkyl, cycloalkyl, acetyl, or

R^5 and R^6 are taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or $N-R^4$ wherein R^4 is as defined above and m is an integer of 2 to 5,




are each independently the same or different and are hydrogen,

alkyl,






aryl,

aralkyl,

acetyl, or




above or R^7 and R^8 taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or $N-R^4$ wherein R^4 and m are as defined above,







halogen,

 CF_3 ,



-170-

CBr₃,CCl₃, orNO₂;

5




10

R^{2a} is CF₃,CCl₃,

-171-


CBr₃, or-N-R¹⁰ wherein R¹⁰ is hydrogen and

5

R¹¹ is -(CH₂)_m-N-R⁵ wherein m, R⁵, and R⁶ are aswherein n, R⁵, and R⁶ are as defined above.

10

11. The compound of Claim 10 wherein

wherein R³, R^{3a}, and R^{3b} are each independently

the same or different and are hydrogen,

alkyl,

aryl,

15

heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

alkyl,

aryl,

aralkyl,

20

acetyl, or

-(CH₂)_m-N-R⁵ wherein R⁵ and R⁶ are each the same

or different and are hydrogen,

25

alkyl, cycloalkyl, acetyl, or

-172-

R^5 and R^6 are taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or $N-R^4$ wherein R^4 is as defined above and m is an integer of 2 to 5,

5 $-(CH_2)_n-N-R^7$ wherein n is zero or an integer of 1 and R^7 and R^8
 $\quad \quad \quad |$
 $\quad \quad \quad R^8$

are each independently the same or different and are hydrogen,

10 $\quad \quad \quad$ alkyl,
 $\quad \quad \quad$ aryl,
 $\quad \quad \quad$ aralkyl,
 $\quad \quad \quad$ acetyl, or

15 $-(CH_2)_m-N-R^5$ wherein R^5 and R^6 are as defined
 $\quad \quad \quad |$
 $\quad \quad \quad R^6$

above or R^7 and R^8 taken together to form a 5- to 7-membered ring optionally containing an oxygen atom or $N-R^4$ wherein R^4 and m are as defined above,

20 $-(CH_2)_n-CON-R^7$ wherein R^7 , R^8 , and n are as defined
 $\quad \quad \quad |$
 $\quad \quad \quad R^8$

above,

25 $-(CH_2)_n-SO_2N-R^7$ wherein R^7 , R^8 , and n are as defined
 $\quad \quad \quad |$
 $\quad \quad \quad R^8$

above,

$-(CH_2)_n-SO_2OR^4$ wherein R^4 and n are as defined above,

30 $-(CH_2)_n-CO_2R^4$ wherein R^4 and n are as defined above,






$-CH_2OR^4$ wherein R^4 is as defined above,

halogen,

-173-


CF₃,CBr₃,CCl₃, orNO₂;

5




10


above, or




above; and



15



-174-



and R⁶ are as defined above.

12. The method according to Claim 7 wherein the mammal is affected with a chemokine-mediated disease selected from the group consisting of psoriasis, or atopic dermatitis, disease associated with pathological angiogenesis (i.e. cancer), asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.

13. A method of treating a chemokine-mediated disease state, wherein the chemokine binds to an IL-8a (CXCR₁) or b (CXCR₂) receptor in a mammal, which comprises administering to said mammal an effective amount of a compound or a pharmaceutically acceptable salt thereof selected from the group consisting of:

N'-[6-Chloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-diethyl-1,2-ethanediamine;

N'-[7-Chloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-diethyl-1,2-ethanediamine;

N'-[6,7-Dichloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-diethyl-1,2-ethanediamine;

6,7-Dichloro-3-(2-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-2-quinoxalinamine;

6-Chloro-3-(2-pyridinyl)-N-[2-(1-pyrrolidinyl)ethyl]-2-quinoxalinamine;

7-Chloro-3-(2-pyridinyl)-N-[2-(1-pyrrolidinyl)ethyl]-2-quinoxalinamine;


-175-

- N'-[6,7-Dimethyl-3-(2-pyridinyl)-2-quinoxaliny]-N,N-diethyl-
1,2-ethanediamine;
6-Chloro-3-(2-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-
2-quinoxalinamine;
5 7-Chloro-3-(2-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-
2-quinoxalinamine;
N'-[6,7-Dimethyl-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl-
1,3-propanediamine;
N'-[6-Chloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl-
10 1,3-propanediamine;
N'-[7-Chloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl-
1,3-propanediamine;
6-Chloro-N-[4-(dimethylamino)cyclohexyl]-3-(2-pyridinyl)-
2-quinoxalinamine;
15 7-Chloro-N-[4-(dimethylamino)cyclohexyl]-3-(2-pyridinyl)-
2-quinoxalinamine;
2,6,7-Trimethyl-3-piperazin-1-yl-quinoxaline;
N,N-Dimethyl-N'-(3-methyl-quinoxalin-2-yl)-propane-
1,3-diamine;
20 2-Methyl-3-(4-methyl-piperazin-1-yl)-quinoxaline;
2-Ethyl-3-piperazin-1-yl-quinoxaline;
6,7-Dichloro-2-methyl-3-piperazin-1-yl-quinoxaline;
2-Phenyl-3-piperidin-1-yl-quinoxaline;
Benzyl-(3-phenyl-quinoxalin-2-yl)-amine;
25 Phenyl-(3-phenyl-quinoxalin-2-yl)-amine;
Methyl-(3-phenyl-quinoxalin-2-yl)-amine;
3-Phenyl-quinoxalin-2-ylamine;
2-Methyl-3-piperazin-1-yl-quinoxaline;
2-Methyl-3-piperidino-quinoxaline;
30 5-[4-(3-Methyl-quinoxalin-2-yl)-piperazin-1-yl]-pentan-1-ol;
N,N-Dimethyl-N'-(3-methyl-quinoxalin-2-yl)-ethane-1,2-diamine;
N,N-Diethyl-N'-(3-methyl-quinoxalin-2-yl)-ethane-1,2-diamine;



-176-

- (3-Methyl-quinoxalin-2-yl)-(3-morpholin-4-yl-propyl)-amine;
N,N-Dimethyl-N'-(3-phenyl-quinoxalin-2-yl)-propane-1,3-diamine;
- 5 3-Phenyl-quinoxalin-2-ylamine;
 2-Methyl-3-pyrrolidin-1-yl-quinoxaline;
 N-(1-Azabicyclo[2.2.2]octan-3-yl)-3-(2-pyridinyl)-2-quinoxalinamine;
- N-[3-(1H-Imidazol-1-yl)propyl]-3-(2-pyridinyl)-2-quinoxalinamine;
- 10 N-[2-(1-Methyl-2-pyrrolidinyl)ethyl]-3-(2-pyridinyl)-2-quinoxalinamine;
- 1-[3-[[3-Pyridinyl)-2-quinoxalinamine]amino]propyl]-2-pyrrolidinone;
- N-[4-(4-Morpholinyl)phenyl]-3-(2-pyridinyl)-2-quinoxalinamine;
- 15 N-(4-Piperidinylmethyl)-3-(2-pyridinyl)-2-quinoxalinamine;
 N-[4-(Dimethylamino)phenyl]-3-(2-pyridinyl)-2-quinoxalinamine;
 N-Methyl-N-[4-[[3-(2-pyridinyl)-2-quinoxaliny]amino]phenyl]-acetamide;
- N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N',N'-dimethyl-
- 20 cyclohexane-1,4-diamine;
 N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-cyclohexane-1,4-diamine;
- 2-[1,4']Bipiperidinyl-1'-yl-6,7-dichloro-3-pyridin-2-yl-quinoxaline;
- (6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(4-
- 25 diethylaminomethyl-phenyl)-amine;
 N'-(6,7-Dichloro-3-furan-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-diamine;
- N'-(6,7-Dichloro-3-thiophen-2-yl-quinoxalin-2-yl)-N,N-dimethyl-propane-1,3-diamine;



-177-




N'-(6,7-Difluoro-3-thiophen-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
butane-1,4-diamine;




5




-178-



N'-[6,7-Dichloro-3-(1H-indol-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;




5 N'-(3-Benzo[b]thiophen-2-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;






N,N-Diethyl-N'-(3-thiophen-2-yl-7-trifluoromethyl-quinoxalin-2-yl)-butane-1,4-diamine;

10 N'-[6,7-Dichloro-3-(5-methyl-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;



-179-



5 N'-(6,7-Dichloro-3-thiazol-2-yl-quinoxalin-2-yl)-N,N-dimethylpropane-1,3-diamine;

N'-(3-[2,2']Bithiophenyl-5-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;


N'-[6,7-Dichloro-3-(5-chloro-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;

10 N'-[6,7-Dichloro-3-(5-methoxy-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;


N'-[6,7-Dichloro-3-(5-propyl-thiophen-2-yl)-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;

15 N'-(3-Benzofuran-2-yl-6,7-dichloro-quinoxalin-2-yl)-N,N-diethyl-butane-1,4-diamine;

-180-





N'-[6,7-Dichloro-3-dibenzothiophen-4-yl-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine;



5



[6,7-Dichloro-3-(5-phenyl-oxazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

[6,7-Dichloro-3-(5-thiophen-2-yl-oxazol)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;



10

-181-



N-(6,7-Dichloro-3-pyridin-3-yl-quinoxalin-2-yl)-N',N'-dimethyl-
cyclohexane-1,4-diamine;

5 N-(6,7-Dichloro-3-pyridin-4-yl-quinoxalin-2-yl)-N',N'-dimethyl-
cyclohexane-1,4-diamine;

N-(6,7-Dimethoxy-3-pyridin-2-yl-quinoxalin-2-yl)-N',N'-dimethyl-
cyclohexane-1,4-diamine;

10 N,N-Dimethyl-N'-(3-pyridin-2-yl-7,8-dihydro-6H-
cyclopenta[g]quinoxalin-2-yl)-cyclohexane-1,4-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
ethane-1,2-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
propane-1,3-diamine;

15 N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
butane-1,4-diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
pentane-1,5-diamine;

20 N-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-pentane-1,5-
diamine;

N'-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-N,N-dimethyl-
hexane-1,6-diamine;

-182-

[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylsulfanyl)-propyl]-dimethylamine;

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(3-morpholin-4-yl-propyl)-amine;

5 (6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(3-methoxypropyl)-amine;

N'-1-[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylamino)-propyl]-N'-1-methyl-propane-1,3-diamine;

10 2-{[3-(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-ylamino)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol;

{4-[4-(2-Chloro-phenyl)-piperidin-1-yl]-butyl-(6,7-dichloro-3-pyridin-2-yl-quinoxalin-2-yl)} amine;

(6,7-Dichloro-3-pyridin-2-yl-quinoxalin-2-yl)-(1-phenyl-4-piperidin-1-yl-butyl)-amine;

15 [6,7-Dichloro-3-(1-ethyl-5-phenyl-imidazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

[6,7-Dichloro-3-(1-phenyl-imidazol-2-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

20 [6,7-Dichloro-3-[1-ethyl-5-(5-methyl-thiophene-2-yl)-imidazol-5-yl]-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine; and

[6,7-Dichloro-3-(1-phenyl-pyrazolo-5-yl)-quinoxalin-2-yl]-(4-pyrrolidin-1-yl-butyl)-amine;

or a pharmaceutically acceptable salt thereof.


14. A pharmaceutical composition comprising a compound according to
25 Claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.

15. A pharmaceutical composition adapted for administration as an agent for treating psoriasis, or atopic dermatitis, disease associated with pathological angiogenesis (i.e. cancer), asthma, chronic obstructive pulmonary disease,
30 adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic


-183-

shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases comprising a therapeutically effective amount of a compound according to Claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.

16. A method for preparing a compound having the Formula Ia



wherein A is selected from the group consisting of:



wherein R³, R^{3a}, and R^{3b} are each independently the

same or different and are hydrogen,

alkyl,

aryl-SO₂-,

aryl,

heteroaryl,

-OR⁴ wherein R⁴ is hydrogen,

alkyl,

aryl,

aralkyl,

acetyl, or

-(CH₂)_m-N-R⁵ wherein



-184-

R^5 and R^6 are each the same or different and are
hydrogen, alkyl, cycloalkyl, acetyl,

$-(CH_2)_m-OH$, or

R^5 and R^6 are taken together to form a 5- to
7-membered ring optionally containing an

oxygen atom or $N-R^4$ wherein R^4 is as

defined above and m is an integer of 2 to 5,

$-(CH_2)_n-N-R^7$ wherein n is zero or an integer of 1 and R^7 and R^8

|
 R^8

are each independently the same or different and are hydrogen,

alkyl,

aryl,

aralkyl,

acetyl, or

$-(CH_2)_m-N-R^5$ wherein R^5 and R^6 are as defined

|
 R^6

above or R^7 and R^8 taken together to form a 5- to

7-membered ring optionally containing an oxygen

atom or $N-R^4$ wherein R^4 and m are as defined

above,

$-(CH_2)_n-CON-R^7$ wherein R^7 , R^8 , and n are as defined above,

|
 R^8

$-(CH_2)_n-SO_2N-R^7$ wherein R^7 , R^8 , and n are as defined above,

|
 R^8

$-(CH_2)_n-SO_2OR^4$ wherein R^4 and n are as defined above,

$-(CH_2)_n-CO_2R^4$ wherein R^4 and n are as defined above,






$-CH_2OR^4$ wherein R^4 is as defined above,

halogen,



-185-

CF₃,CBr₃,CCl₃, orNO₂,




5

wherein R³ and R^{3a} are as defined above,wherein R³ and R^{3a} are as defined above,wherein R³ and R^{3a} are as defined above,wherein R³ and R^{3a} are as defined above,wherein R³ and R^{3a} are as defined above,






10

wherein R³ and R^{3a} are as defined above,wherein R³ and R^{3a} are as defined above, and



-186-




5




-187-

and R^3 and R^{3a} are as defined above,


above,




above,



above,




above,




above,

-188-




above,




above,


5



above,




above,




10

above,




above,


-189-

wherein R³, R^{3a}, and R^{3b} are as


defined above,

wherein R³, R^{3a}, and R^{3b} are as defined



above,

wherein R³, R^{3a}, and R^{3b} are as defined

above,

wherein R³, R^{3a}, and R^{3b} are as defined


above,

wherein R³, R^{3a}, and R^{3b} are as defined above,wherein R³, R^{3a}, and R^{3b} are as defined


above,

10

-190-




above,






above,


5






above,







10




-191-

wherein R^3 is as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as defined

above,

wherein R^3 and R^{3a} are as defined above,wherein R^3 and R^{3a} are as defined above,wherein R^3 and R^{3a} are as defined above,wherein R^3 , R^{3a} , and R^{3b} are as


defined above,

wherein R^3 , R^{3a} , and R^{3b} are as


defined above,

10

-192-



wherein R³, R^{3a}, and R^{3b} are as

defined above,



halogen, or

alkoxy, with the proviso




chloro, R¹ is not wherein R³ is hydrogen;

and

R¹⁰ is hydrogen,

alkyl, or

aralkyl, and


wherein n, R⁵, and R⁶ are as defined above,-(CH₂)_m-N-R⁵ wherein R⁵, R⁶, and m are as defined above,-(CH₂)_m-N-C-N-R¹² wherein R¹² and R^{12a} are each


-193-



independently the same or different and are hydrogen,
alkyl, or aryl, or taken together can form a 5- to
7-membered ring, and

R¹³ is hydrogen or alkyl, and


m is as defined above,




above, $-(CH_2)_m-$  $N-R^9$ wherein R⁹ and m are
as defined above,




above,





defined above,



above,




-194-




R¹⁰ and R¹¹ when taken together can form a 5- to 7-membered ring optionally containing an oxygen atom or N-R⁴ wherein R⁴ is as defined above;

or a pharmaceutically acceptable salt thereof comprises reacting a compound of Formula III



III

wherein A and R¹ are as defined above with a compound of Formula IV



IV

wherein R¹⁰ and R¹¹ are as defined above in a solvent to afford a compound of Formula Ia.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/02581

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D405/04 C07D409/04 C07D403/04 C07D401/04 C07D241/44
C07D417/04 C07D413/04 A61K31/495

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ED. ELSLAGER ET AL.: "POT. ANTIMALARIAL AGENTS." JOURNAL OF MEDICINAL CHEMISTRY., vol. 11, no. 3, May 1968, pages 630-631, XP002100497 WASHINGTON US see page 630 - page 631 ---	1, 14-16
X	CHEMICAL ABSTRACTS, vol. 123, no. 28, 1995 Columbus, Ohio, US; abstract no. 55808h, A. MONGE ET AL.: "NEW 5-HT3 ANTAGONISTS." page 917; XP002100501 see abstract & AN. R. ACAD. FARM., vol. 60, no. 1, 1994, pages 91-104, --- -/-	1, 2, 7-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 April 1999

Date of mailing of the international search report

06/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

In. tional Application No

PCT/US 99/02581

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 574 429 A (SHELL) 10 September 1980 see examples 9,11 ---	1
A	EP 0 288 898 A (HOECHST) 2 November 1988 see page 1 - page 2; claims; examples 13,24,28,32 ---	1,7-14
A	M. LORIGA ET AL.: "QUINOXALINE CHEMISTRY.PART 4." FARMACO., vol. 50, no. 5, 1995, pages 289-301, XP002100549 PAVIA IT see page 289 - page 295 -----	1,2, 14-16

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 02581

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7-13
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 7-13
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/02581

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
GB 1574429	A	10-09-1980	NONE	
EP 288898	A	02-11-1988	DE 3713872 A	17-11-1988
			AT 66220 T	15-08-1991
			AU 600121 B	02-08-1990
			AU 1509388 A	27-10-1988
			DE 3864179 A	19-09-1991
			DK 222588 A	26-10-1988
			GR 3002884 T	25-01-1993
			JP 63280080 A	17-11-1988
			PH 24258 A	04-05-1990
			PT 87307 A,B	01-05-1988
			US 4943576 A	24-07-1990